{"gene":"MYD88","run_date":"2026-04-29T11:37:56","timeline":{"discoveries":[{"year":1997,"finding":"MyD88 is recruited to the IL-1 receptor complex following IL-1 stimulation and mediates association of IRAK with the receptor; the death domain-containing N-terminus of MyD88 activates NF-κB, and its C-terminus interacts with the IL-1 receptor to block NF-κB activation induced by IL-1 but not TNF.","method":"Co-immunoprecipitation, dominant-negative overexpression, deletion mutagenesis","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP with domain mutagenesis, foundational paper replicated across multiple studies","pmids":["9430229"],"is_preprint":false},{"year":1997,"finding":"MyD88 acts as a death domain-containing adaptor downstream of the human Toll receptor and IL-1R, coupling these receptors to IRAK and TRAF6 to activate NF-κB; Toll and IL-1R signaling pathways differ in AP-1 activation.","method":"Overexpression, dominant-negative constructs, reporter assays in cell lines","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, foundational paper with strong independent replication","pmids":["9734363"],"is_preprint":false},{"year":1997,"finding":"MyD88 is identified as a proximal mediator of IL-1R-induced NF-κB activation alongside IRAK-2; dominant-negative forms of MyD88 attenuate IL-1R-mediated NF-κB activation, and both MyD88 and IRAK-2 associate with the IL-1R signaling complex.","method":"Dominant-negative overexpression, co-immunoprecipitation, NF-κB reporter assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP plus epistasis, replicated by multiple independent labs","pmids":["9374458"],"is_preprint":false},{"year":1997,"finding":"MyD88 has a modular architecture with an N-terminal death domain and C-terminal TIR domain; it forms homodimers via DD-DD and TIR-TIR interactions; overexpression activates NF-κB and JNK through its DD; a point mutation (F56N, MyD88-lpr) preventing DD dimerization blocks NF-κB and JNK activation; MyD88-induced NF-κB activation requires TRAF6 and IRAK.","method":"In vivo dimerization assays, co-immunoprecipitation, mutagenesis, reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis plus functional assays, multiple orthogonal methods","pmids":["9575168"],"is_preprint":false},{"year":1997,"finding":"MyD88 gene structure spans five exons with the first exon encoding the complete death domain; the gene is evolutionarily conserved and maps to mouse chromosome 9 distal region and human chromosome 3p22-p21.3; MyD88 is broadly expressed in many adult tissues, not restricted to myeloid cells.","method":"Interspecific backcross mapping, Northern blot, RT-PCR, zooblot analysis","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 — direct genetic mapping and expression characterization, single study","pmids":["9344657"],"is_preprint":false},{"year":1999,"finding":"MyD88 knockout mice completely lack LPS shock response, B cell proliferative response, and cytokine secretion by macrophages in response to LPS; however, NF-κB and MAP kinase activation are not abolished, revealing a MyD88-dependent and a MyD88-independent pathway downstream of LPS/TLR4.","method":"MyD88 knockout mice, cytokine ELISA, NF-κB activation assays, proliferation assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — clean genetic KO with multiple defined phenotypic readouts, highly cited foundational study","pmids":["10435584"],"is_preprint":false},{"year":2000,"finding":"MyD88 mediates both apoptosis and NF-κB activation downstream of TLR2 stimulated by bacterial lipoproteins; the two pathways bifurcate at MyD88; MyD88 signals apoptosis via FADD and caspase-8; MyD88 directly binds FADD.","method":"Co-immunoprecipitation, dominant-negative constructs, apoptosis assays, caspase activity assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — direct Co-IP with FADD plus functional epistasis, multiple orthogonal methods","pmids":["10880445"],"is_preprint":false},{"year":2000,"finding":"Tollip is present in a pre-formed complex with IRAK before IL-1β stimulation; upon IL-1β treatment, Tollip-IRAK complexes are recruited to the receptor complex through Tollip binding to IL-1RAcP; co-recruited MyD88 triggers IRAK autophosphorylation; IRAK then dissociates from Tollip.","method":"Co-immunoprecipitation, overexpression, NF-κB reporter assays","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP revealing ordered assembly, replicated in multiple contexts","pmids":["10854325"],"is_preprint":false},{"year":2001,"finding":"MyD88-deficient dendritic cells can undergo functional maturation (upregulation of costimulatory molecules, enhanced APC activity) in response to LPS despite lacking cytokine production, demonstrating a MyD88-independent pathway downstream of TLR4; TLR9 signaling for DC maturation requires MyD88.","method":"MyD88 knockout mice, flow cytometry for costimulatory molecules, in vivo analysis, mixed leukocyte reaction","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — clean genetic KO with multiple phenotypic readouts, established MyD88-independent pathway","pmids":["11313410"],"is_preprint":false},{"year":2001,"finding":"Micrococci and peptidoglycan activate a TLR2→MyD88→IRAK→TRAF6→NIK→IKK→NF-κB pathway leading to IL-8 transcription; dominant-negative MyD88 completely inhibits this pathway.","method":"Dominant-negative constructs, NF-κB reporter assays, HEK293 overexpression system","journal":"Infection and immunity","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis via dominant negatives defining pathway order, single study","pmids":["11254583"],"is_preprint":false},{"year":2001,"finding":"Mal (TIRAP) is an additional TIR-domain adaptor required for TLR4 signaling that forms heterodimers with MyD88; Mal activates NF-κB via IRAK-2 (not IRAK-1, which MyD88 requires); Mal associates directly with TLR4 and a dominant-negative Mal blocks TLR4/LPS-induced NF-κB but not IL-1RI or IL-18R signaling.","method":"Co-immunoprecipitation, dominant-negative constructs, reporter assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, reciprocal Co-IP, highly cited foundational paper","pmids":["11544529"],"is_preprint":false},{"year":2002,"finding":"IRAK-4 directly interacts with IRAK-1 and TRAF6 in an IL-1-dependent manner; IRAK-4 phosphorylates IRAK-1 and acts upstream of IRAK-1 in MyD88-dependent signaling; dominant-negative IRAK-4 blocks IL-1-induced activation and modification of IRAK-1.","method":"Co-immunoprecipitation, kinase assays, dominant-negative constructs, NF-κB reporter assays","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro kinase assay plus Co-IP and epistasis, replicated widely","pmids":["11960013"],"is_preprint":false},{"year":2003,"finding":"MyD88s (alternatively spliced short form lacking the intermediate domain) acts as a dominant-negative inhibitor of IL-1/LPS-induced NF-κB activation because it fails to recruit IRAK-4; in the presence of MyD88s, IRAK-1 is not phosphorylated and does not activate NF-κB.","method":"Co-immunoprecipitation, overexpression, NF-κB reporter assays, phosphorylation analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — direct Co-IP demonstrating differential IRAK-4 recruitment as molecular explanation","pmids":["12538665"],"is_preprint":false},{"year":2004,"finding":"MyD88 forms a complex with IRF7 (but not IRF3) through its death domain interacting with an inhibitory domain of IRF7, leading to activation of IFN-α-dependent promoters; TRAF6 also binds and activates IRF7, and TRAF6 ubiquitin ligase activity is required for IRF7 activation downstream of TLR7/8/9-MyD88 signaling.","method":"Co-immunoprecipitation, reporter assays, ubiquitination assays, knockout cells","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — direct Co-IP defining complex composition with functional validation of each component","pmids":["15361868"],"is_preprint":false},{"year":2005,"finding":"IRF-5 acts downstream of the TLR-MyD88 signaling pathway for induction of proinflammatory cytokines (IL-6, IL-12, TNF-α); IRF-5 interacts with and is activated by MyD88 and TRAF6; TLR activation results in nuclear translocation of IRF-5 to activate cytokine gene transcription.","method":"Co-immunoprecipitation, IRF-5 knockout mice, subcellular fractionation, reporter assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — genetic KO plus direct Co-IP plus nuclear translocation, highly replicated","pmids":["15665823"],"is_preprint":false},{"year":2006,"finding":"TIRAP/Mal contains a phosphatidylinositol 4,5-bisphosphate (PIP2) binding domain that mediates its recruitment to the plasma membrane; TIRAP then facilitates delivery of MyD88 to activated TLR4 to initiate signal transduction, establishing a two-step adaptor recruitment mechanism.","method":"Subcellular localization by live imaging, PIP2 binding assays, dominant-negative constructs, co-immunoprecipitation","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — direct localization with functional consequence established by multiple orthogonal methods","pmids":["16751103"],"is_preprint":false},{"year":2006,"finding":"MyD88 increases the half-life (but not synthesis) of IFN-γ-induced mRNA transcripts encoding TNF and IP-10; IFN-γ stimulation triggers physical association between IFN-γR1 and MyD88; transcript stabilization requires MLK3 and p38 MAPK activation and AU-rich elements in the 3′UTR.","method":"mRNA half-life assays, co-immunoprecipitation of IFN-γR1 and MyD88, kinase inhibitors, mutagenesis","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — direct Co-IP plus functional mRNA stability assays with mutagenesis, novel mechanism in single rigorous study","pmids":["16491077"],"is_preprint":false},{"year":2007,"finding":"The BB-loop of the MyD88 TIR domain is critical for MyD88 homodimerization and for recruitment of IRAK1 and IRAK4; a peptidomimetic (ST2825) modeled on this BB-loop inhibits MyD88 TIR-domain homodimerization specifically (not DD homodimerization), blocks IRAK1/IRAK4 recruitment, and inhibits IL-1β-mediated NF-κB activation.","method":"Co-immunoprecipitation, peptidomimetic inhibition, NF-κB reporter assays, in vivo cytokine assays","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 — structure-based inhibitor with mechanistic validation by Co-IP, multiple orthogonal assays","pmids":["17548806"],"is_preprint":false},{"year":2007,"finding":"MyD88-5 (a MyD88 family member) is preferentially expressed in neurons, colocalizes in part with mitochondria, co-immunoprecipitates with JNK3, and recruits JNK3 from cytosol to mitochondria; hippocampal neurons from MyD88-5-deficient mice are protected from death after oxygen-glucose deprivation.","method":"Transgenic GFP mice, subcellular fractionation, co-immunoprecipitation, knockout neurons, live/death assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — direct Co-IP plus fractionation with functional KO phenotype, multiple methods","pmids":["17724133"],"is_preprint":false},{"year":2008,"finding":"MyD88 acts as a scaffold coupling protein kinase Cε (PKCε) to TLRs; LPS-induced PKCε phosphorylation at Ser-346 and Ser-368 promotes 14-3-3β binding and TLR4 recruitment, all dependent on MyD88 expression; PKCε phosphorylation is required for TLR4- and TLR2-induced NF-κB activation.","method":"Co-immunoprecipitation, MyD88 KO mouse cells, MyD88 knockdown, overexpression, phosphorylation-site mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods in KO cells plus mutagenesis confirming functional sites","pmids":["18458086"],"is_preprint":false},{"year":2008,"finding":"Human individuals with autosomal recessive MyD88 deficiency suffer from recurrent life-threatening pyogenic bacterial infections (especially pneumococcal) but are otherwise healthy, demonstrating that MyD88-dependent TLR/IL-1R signaling is essential for protective immunity to a narrow range of pyogenic bacteria but redundant for defense against most natural infections.","method":"Human genetic study, functional cellular assays confirming loss of MyD88-dependent signaling in patient cells","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — natural human loss-of-function with cellular validation, replicated in follow-up cohort studies","pmids":["18669862"],"is_preprint":false},{"year":2010,"finding":"Crystal structure of the MyD88-IRAK4-IRAK2 death domain complex reveals a left-handed helical oligomer ('Myddosome') consisting of 6 MyD88, 4 IRAK4, and 4 IRAK2 DDs; assembly is hierarchical (MyD88 recruits IRAK4, then MyD88-IRAK4 recruits IRAK2/IRAK1); composite binding sites are required, and specificities are dictated by molecular complementarity and surface electrostatics.","method":"X-ray crystallography, mutagenesis, functional validation of interface residues","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mutagenesis validation, foundational structural study","pmids":["20485341"],"is_preprint":false},{"year":2010,"finding":"Two human MYD88 variants (S34Y and R98C) in the death domain severely reduce NF-κB activation due to impaired MyD88 homo-oligomerization and reduced IRAK4 interaction; MyD88 homo-oligomerization and IRAK4 interaction are also modulated by the MyD88 TIR domain and IRAK4 kinase domain; differential signaling effects suggest receptor specificities exist at the Myddosome level.","method":"Functional NF-κB assays, co-immunoprecipitation, structural modeling, epidemiological case-control analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — structure-guided mutagenesis with Co-IP and functional assays, multiple orthogonal methods","pmids":["20966070"],"is_preprint":false},{"year":2010,"finding":"IRAK1 and IRAK4 directly phosphorylate the adaptor Mal, leading to its ubiquitination and proteasomal degradation upon LPS stimulation; MyD88 is NOT a substrate for either IRAK and does not undergo degradation, distinguishing the turnover mechanisms of these two adaptors.","method":"In vitro kinase assays, co-immunoprecipitation, ubiquitination assays, siRNA knockdown, IRAK1/4 inhibitor","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay demonstrating direct phosphorylation plus functional validation","pmids":["20400509"],"is_preprint":false},{"year":2010,"finding":"The MYD88 L265P mutation in ABC DLBCL constitutively assembles a signaling complex with IRAK1 and IRAK4, leading to IRAK4 kinase activity, IRAK1 phosphorylation, NF-κB signaling, JAK kinase activation of STAT3, and secretion of IL-6, IL-10 and IFN-β; L265P is a gain-of-function driver mutation in the TIR domain at an evolutionarily invariant hydrophobic core residue.","method":"RNA interference screening, RNA resequencing, co-immunoprecipitation, kinase activity assays, cytokine measurements, rescue experiments with wild-type vs. mutant MyD88","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including Co-IP of complex, kinase assays, and genetic rescue, replicated widely","pmids":["21179087"],"is_preprint":false},{"year":2012,"finding":"MYD88 L265P somatic mutation triggers IRAK-mediated NF-κB signaling; inhibition of MYD88 signaling reduces IκBα and NF-κB p65 phosphorylation and NF-κB nuclear staining in Waldenström macroglobulinemia cells expressing MYD88 L265P.","method":"Whole-genome sequencing, Sanger sequencing validation, pharmacological inhibition of MyD88 signaling with functional readouts","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 2 — functional validation of mutation effect plus pharmacological intervention with mechanistic readouts","pmids":["22931316"],"is_preprint":false},{"year":2012,"finding":"MYD88 directly binds ARNO (CYTH2) and signals through ARF6 to disrupt endothelial vascular stability in response to IL-1β via an NF-κB-independent pathway; ARNO binds directly to MyD88, establishing MYD88-ARNO-ARF6 as a proximal IL-1β signaling pathway distinct from the canonical NF-κB route.","method":"Co-immunoprecipitation, siRNA knockdown, in vitro cell model, animal models of inflammatory arthritis and acute inflammation","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — direct Co-IP plus multiple in vivo models with defined mechanism, single rigorous study","pmids":["23143332"],"is_preprint":false},{"year":2012,"finding":"MyD88 exerts a cell-intrinsic function in RAS-mediated transformation of keratinocytes through an autocrine IL-1α→IL-1R→MyD88→NF-κB loop; loss of MyD88 in keratinocytes expressing oncogenic RAS impairs proinflammatory gene upregulation and differentiation block without abolishing their hyperproliferation.","method":"Knockout mice, orthotopic grafts, pharmacological NF-κB inhibition, genetic and pharmacological approaches","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with orthotopic transplants, multiple genetic and pharmacological validation approaches","pmids":["22908325"],"is_preprint":false},{"year":2016,"finding":"MyD88 and downstream IRAK4 intrinsically control pericyte migration and conversion to myofibroblasts; MyD88-specific ablation in pericytes protects against kidney fibrosis; pericytes also activate NLRP3 inflammasome through MyD88, leading to IL-1β and IL-18 secretion, which feeds back through pericyte MyD88.","method":"Conditional MyD88 knockout in pericytes, IRAK4 inhibitor in vivo, cell migration assays, fibrosis readouts","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — conditional genetic KO with cell-specific phenotype plus pharmacological validation","pmids":["27869651"],"is_preprint":false},{"year":2016,"finding":"MyD88 NEDDylation antagonizes its ubiquitination; NEDD8 modification negatively regulates MyD88 dimerization and suppresses MyD88-dependent NF-κB signaling; upon IL-1β stimulation, MyD88 NEDDylation decreases while ubiquitination increases; deNEDDylase NEDP1 regulates this balance.","method":"Co-immunoprecipitation, ubiquitination/NEDDylation assays, NF-κB reporter assays, NEDP1 overexpression","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — direct biochemical assays with functional readout, single lab study","pmids":["27864145"],"is_preprint":false},{"year":2017,"finding":"MyD88 promotes myoblast fusion in a cell-autonomous manner; MyD88 protein levels increase during in vitro myogenesis and muscle growth; deletion of MyD88 impairs myoblast fusion without affecting survival, proliferation, or differentiation; MyD88 regulates non-canonical NF-κB and canonical Wnt signaling during myogenesis.","method":"MyD88 conditional knockout, in vitro differentiation assays, in vivo muscle overload model, lentiviral overexpression","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — conditional genetic KO plus OE with specific cell-autonomous phenotype, multiple orthogonal validations","pmids":["29158520"],"is_preprint":false},{"year":2017,"finding":"TRAF6 E3 ligase activity is not solely responsible for K63-linked ubiquitin chain formation in IL-1 signaling; Pellino1 and Pellino2 generate the K63-Ub chains required when TRAF6 E3 ligase is inactive; IL-1-induced ubiquitylation of IRAK1, IRAK4, and MyD88 requires combined activity of TRAF6 and Pellinos, as it is abolished only in TRAF6/Pellino1/Pellino2 triple-KO cells.","method":"Triple-knockout cells, E3 ligase-inactive knockin mice, in vitro ubiquitination assays, TAK1 activation assays","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro reconstitution plus genetic triple-KO plus knockin mice, multiple orthogonal methods","pmids":["28404732"],"is_preprint":false},{"year":2018,"finding":"The constitutively active MyD88 L265P mutant is transferred via extracellular vesicles (EVs) into recipient mast cells and macrophages, where it recruits endogenous wild-type MyD88 and triggers proinflammatory signaling in the absence of receptor activation; MyD88-loaded EVs were detected in bone marrow aspirates of Waldenström macroglobulinemia patients.","method":"Extracellular vesicle isolation, fluorescent tracking, co-immunoprecipitation, NF-κB activation assays, in vivo mouse experiments, patient samples","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — functional EV transfer with mechanistic validation in vitro and in vivo plus patient sample confirmation","pmids":["29358175"],"is_preprint":false},{"year":2020,"finding":"SPOP (Cullin 3-based ubiquitin ligase adaptor) recognizes the intermediate domain of MyD88 and degrades it through the proteasome; knockdown or knockout of SPOP leads to elevated MyD88 protein; SPOP negatively regulates NF-κB activity and IL-1β production upon LPS challenge; Spop-deficient mice are more susceptible to Salmonella infection.","method":"Co-immunoprecipitation, ubiquitination assays, gene knockout (chicken cells and mouse), proteasome inhibition, in vivo infection model","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 — direct biochemical identification of E3 adaptor-substrate interaction plus genetic KO in two species with functional readouts","pmids":["32365080"],"is_preprint":false},{"year":2021,"finding":"E3 ligase RNF138 catalyzes K63-linked non-proteolytic polyubiquitination specifically of MYD88 L265P (not wild-type MYD88), enhancing IRAK recruitment and NF-κB activation; A20 mediates K48-linked polyubiquitination of RNF138 for proteasomal degradation, acting as a negative feedback; mutation of MYD88 L265P ubiquitination sites abolishes constitutive NF-κB activation.","method":"Co-immunoprecipitation, ubiquitination assays, RNF138 knockdown, mutagenesis of ubiquitination sites, NF-κB reporter assays, lymphoma growth assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — direct biochemical dissection with mutagenesis and multiple orthogonal methods in a single rigorous study","pmids":["33025009"],"is_preprint":false},{"year":2022,"finding":"IRAK4 scaffold (independent of its kinase activity) is required for activation of TRAF6 by both MYD88 and TRIF downstream of TLR4, integrating the two signaling pathways; IRAK4 kinase activity is essential for MYD88 signaling; IRAK4 thus has dual roles as kinase and scaffold in TLR4 signaling.","method":"IRAK4 knockout and kinase-dead knockin cell lines, TRAF6 activation assays, cytokine production assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — genetic KO plus kinase-dead knockin with multiple functional readouts, multiple orthogonal methods","pmids":["35977521"],"is_preprint":false},{"year":2022,"finding":"MYD88 directly blocks autophagic degradation of STING1, thereby promoting STING1-dependent ACOD1 (IRG1) expression through IRF3/JUN-mediated transcription; MYD88 (not CGAS) favors this STING1-dependent ACOD1 expression; conditional deletion of STING1 in myeloid cells prevents itaconate production and worsens endotoxemia and sepsis.","method":"Co-immunoprecipitation, STING1 and MYD88 knockout/conditional knockout mice, autophagy assays, reporter assays, sepsis model","journal":"iScience","confidence":"High","confidence_rationale":"Tier 2 — direct Co-IP plus conditional KO in vivo with mechanistic pathway dissection","pmids":["35769880"],"is_preprint":false},{"year":2022,"finding":"Osteocyte MYD88 activation by bacterial PAMPs upregulates RANKL by increasing binding of transcription factors CREB and STAT3 to Rankl enhancers and by suppressing K48-ubiquitination of CREB/CBP and STAT3; osteocyte-specific MYD88 restoration in KO mice reconstitutes osteolysis with inflammatory cell infiltration.","method":"Conditional MYD88 knockout in osteocytes, conditional MYD88 restoration, ChIP assays, ubiquitination assays, in vivo calvarial injection and periodontitis models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — conditional genetic KO and restoration with ChIP and ubiquitination mechanistic dissection","pmids":["36333322"],"is_preprint":false},{"year":2009,"finding":"PYK2 interacts with MyD88 via the death domain of MyD88 in vitro and in macrophages; this interaction increases upon LPS stimulation; PYK2-deficient macrophages show reduced IκB phosphorylation/degradation and decreased NF-κB activation and IL-1β expression, placing PYK2 upstream of NF-κB in MyD88-dependent signaling.","method":"Co-immunoprecipitation, PYK2 knockout macrophages, NF-κB reporter assays, phosphorylation assays","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 3 — single Co-IP with KO macrophage functional validation, single lab","pmids":["19955209"],"is_preprint":false},{"year":2019,"finding":"BANK1 interacts with TRAF6 and MyD88 via its TIR domain as demonstrated by co-immunoprecipitation; the natural BANK1-40C variant shows increased binding to MyD88; BANK1 colocalizes with TLR7 and TLR9 in B cells, and stimulation increases co-localization with MyD88; BANK1 TIR domain is important for K63-linked polyubiquitination.","method":"Co-immunoprecipitation, point mutations, decoy peptides, confocal microscopy, IL-8 production assays","journal":"Cellular & molecular immunology","confidence":"Medium","confidence_rationale":"Tier 3 — single Co-IP with partial functional follow-up, single lab","pmids":["31243359"],"is_preprint":false},{"year":2013,"finding":"MyD88 determines cell fate decision (apoptosis vs. necroptosis) after UV irradiation in macrophages; MyD88-deficient macrophages show decreased apoptosis and increased necroptotic signaling (elevated RIP1, TNF-α release, reduced caspase-3 cleavage); TLR4-deficient macrophages phenocopy MyD88-deficient cells, placing TLR4-MyD88 axis as key regulator of UV-induced cell death pathway choice.","method":"MyD88 and TLR4 KO macrophages, caspase assays, DNA laddering, TLR-specific KO comparison","journal":"Innate immunity","confidence":"Medium","confidence_rationale":"Tier 2 — multiple KO models with mechanistic cell-death pathway readouts, single lab","pmids":["24048771"],"is_preprint":false},{"year":2016,"finding":"TLR3 acts through MYD88 to negatively regulate DISC1 expression in neurons, impairing dendritic arborization; impaired dendritic morphology from TLR3 activation is rescued by MYD88 deficiency or DISC1 overexpression; this MYD88-mediated suppression is cytokine-independent.","method":"Cultured neurons, in vivo mouse brain, MYD88 knockout, TLR3 agonists, DISC1 overexpression rescue","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO rescue with specific molecular target identified, single lab","pmids":["27979975"],"is_preprint":false},{"year":2022,"finding":"MyD88 L265P is found in normal precursor and mature B lymphocytes from patients with lymphoplasmacytic lymphoma, establishing MYD88 L265P as a preneoplastic (pre-malignant) event; a mouse model based on mutated MYD88 in B cell precursors combined with BCL2 overexpression reconstitutes lymphoplasmacytic lymphoma.","method":"Multi-stage B lineage sequencing, whole-genome sequencing, transgenic mouse model","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 — sequencing of sorted B cell populations plus in vivo mouse model validation, single study","pmids":["35044826"],"is_preprint":false}],"current_model":"MYD88 is a bipartite adaptor protein (N-terminal death domain + C-terminal TIR domain) that, upon TLR/IL-1R activation, is recruited to the receptor complex via TIR-TIR interactions, forms a left-handed helical 'Myddosome' with IRAK4 and IRAK2/IRAK1 death domains (6:4:4 stoichiometry), recruits and activates IRAK4 (which phosphorylates IRAK1), and drives downstream K63-ubiquitination by TRAF6/Pellino E3 ligases to activate NF-κB, MAPK, IRF5, and IRF7; additionally, MYD88 scaffolds PKCε to TLRs, associates with IFN-γR1 to stabilize mRNA post-transcriptionally, directly binds ARNO/ARF6 to disrupt vascular integrity independently of NF-κB, blocks autophagic degradation of STING1 to promote IRF3/JUN-driven ACOD1 expression, regulates cell fate between apoptosis and necroptosis, and promotes myoblast fusion and neuronal homeostasis; gain-of-function mutation L265P spontaneously assembles the Myddosome and drives constitutive NF-κB/STAT3 signaling in B-cell malignancies through mutation-specific RNF138-mediated K63-ubiquitination, while negative regulation is achieved by NEDDylation antagonizing ubiquitination, SPOP-mediated proteasomal degradation via the intermediate domain, and the alternatively spliced MyD88s isoform failing to recruit IRAK4."},"narrative":{"teleology":[{"year":1997,"claim":"The fundamental question of how IL-1R and Toll receptor signals reach NF-κB was resolved by identifying MYD88 as a bipartite DD–TIR adaptor that is recruited to the receptor complex via its TIR domain and activates IRAK and TRAF6 via its death domain, establishing the core signaling architecture of TLR/IL-1R pathways.","evidence":"Co-immunoprecipitation, dominant-negative overexpression, deletion mutagenesis, reporter assays across multiple labs","pmids":["9430229","9734363","9374458","9575168"],"confidence":"High","gaps":["Stoichiometry and structural basis of the MYD88 signaling complex were unknown","Whether MYD88 served all TLRs or only a subset was not established","Mechanism of IRAK activation by MYD88 was not resolved"]},{"year":1999,"claim":"The in vivo requirement for MYD88 in innate immunity was established by knockout mice that lacked LPS shock, macrophage cytokine responses, and B cell proliferation—but retained delayed NF-κB activation—revealing a bifurcation into MYD88-dependent and MYD88-independent TLR4 pathways.","evidence":"MYD88 knockout mice with cytokine ELISA, NF-κB assays, and proliferation assays","pmids":["10435584"],"confidence":"High","gaps":["Identity of the MYD88-independent adaptor (later TRIF) was unknown","Whether MYD88 was required for all TLRs beyond TLR4 had not been tested"]},{"year":2000,"claim":"MYD88 was shown to bifurcate signaling not only toward NF-κB but also toward apoptosis through direct binding of FADD and caspase-8 downstream of TLR2, establishing MYD88 as a decision node for cell fate.","evidence":"Co-immunoprecipitation of MyD88–FADD, dominant-negative constructs, caspase activity assays","pmids":["10880445"],"confidence":"High","gaps":["How the choice between apoptotic and NF-κB pathways is regulated at MYD88 was not resolved","Whether necroptotic pathways are also governed by MYD88 was unexplored"]},{"year":2001,"claim":"The adaptor TIRAP/Mal was identified as a TIR-domain heterodimer partner that bridges TLR4 to MYD88, establishing a two-adaptor recruitment model later shown to involve PIP2-mediated membrane targeting of TIRAP.","evidence":"Co-immunoprecipitation, dominant-negative Mal, reporter assays; followed by live imaging of PIP2-dependent Mal localization (2006)","pmids":["11544529","16751103"],"confidence":"High","gaps":["Whether TIRAP serves all TLRs or only a subset was debated","Structural basis for the TIRAP–MYD88 heterodimer was not resolved"]},{"year":2003,"claim":"The alternatively spliced isoform MyD88s was shown to act as a natural dominant-negative inhibitor because it lacks the intermediate domain required to recruit IRAK-4, providing the first evidence of negative regulation at the level of MYD88 itself.","evidence":"Co-immunoprecipitation demonstrating loss of IRAK-4 binding by MyD88s, phosphorylation analysis, NF-κB reporter assays","pmids":["12538665"],"confidence":"High","gaps":["Physiological contexts and regulation of MyD88s splicing were not defined","Whether MyD88s affects IRF signaling was untested"]},{"year":2005,"claim":"MYD88 was connected to interferon regulatory factor signaling: its death domain directly binds IRF7 to drive IFN-α responses downstream of TLR7/8/9, and IRF5 acts downstream of MYD88-TRAF6 to induce proinflammatory cytokine genes, diversifying MYD88 output beyond NF-κB.","evidence":"Co-immunoprecipitation, IRF5 knockout mice, nuclear translocation, ubiquitination assays, reporter assays","pmids":["15361868","15665823"],"confidence":"High","gaps":["How pathway choice between NF-κB, IRF5, and IRF7 is determined at the Myddosome was unknown","Whether IRF5 and IRF7 are activated through the same or distinct MYD88 complexes was unresolved"]},{"year":2008,"claim":"MYD88 was found to scaffold PKCε to TLRs and to associate with IFN-γR1 for post-transcriptional mRNA stabilization, expanding its function beyond TLR/IL-1R to a non-canonical IFN-γ signaling role and to kinase scaffolding.","evidence":"Co-immunoprecipitation in MYD88 KO cells, phosphorylation-site mutagenesis, mRNA half-life assays","pmids":["18458086","16491077"],"confidence":"High","gaps":["Structural basis for MYD88–IFN-γR1 and MYD88–PKCε interactions was unknown","Whether MYD88 scaffolding of PKCε is relevant to all TLRs was not tested comprehensively"]},{"year":2008,"claim":"Human autosomal recessive MYD88 deficiency was shown to cause life-threatening pyogenic bacterial infections but surprising resistance to most other pathogens, defining the essential and redundant roles of MYD88-dependent signaling in human immunity.","evidence":"Human genetic study with functional cellular assays confirming loss of MYD88-dependent signaling in patient cells","pmids":["18669862"],"confidence":"High","gaps":["Why only a narrow range of pyogenic bacteria requires MYD88-dependent defense was not mechanistically explained","Long-term outcomes and compensatory mechanisms in MYD88-deficient patients were incompletely characterized"]},{"year":2010,"claim":"The crystal structure of the Myddosome (6 MyD88 DD : 4 IRAK4 DD : 4 IRAK2 DD) revealed a left-handed helical assembly with hierarchical recruitment and composite binding interfaces, providing the structural basis for signal amplification and explaining why specific DD mutations (S34Y, R98C) impair oligomerization.","evidence":"X-ray crystallography with mutagenesis validation of interface residues; functional assays of human DD variants","pmids":["20485341","20966070"],"confidence":"High","gaps":["How the TIR domain oligomer connects to the DD oligomer structurally was not resolved","Full-length MYD88 structure remained unavailable","How Myddosome disassembly is regulated was unknown"]},{"year":2010,"claim":"The MYD88 L265P somatic mutation was identified as an oncogenic driver in ABC-DLBCL that constitutively assembles a Myddosome complex activating IRAK4/IRAK1, NF-κB, and JAK-STAT3 signaling—later confirmed in Waldenström macroglobulinemia—establishing MYD88 as a bona fide oncogene in B-cell malignancies.","evidence":"RNAi screening, RNA resequencing, Co-IP of constitutive complex, kinase assays, WGS in WM patients, pharmacological inhibition","pmids":["21179087","22931316"],"confidence":"High","gaps":["Mechanism of spontaneous Myddosome assembly by L265P was not structurally resolved","Whether L265P cooperates with specific secondary mutations was unclear"]},{"year":2012,"claim":"MYD88 was shown to signal through a non-canonical NF-κB-independent pathway by directly binding ARNO/CYTH2 to activate ARF6 and disrupt vascular integrity, demonstrating functional outputs beyond transcription factor activation.","evidence":"Co-immunoprecipitation, siRNA knockdown, endothelial cell models, in vivo inflammatory arthritis models","pmids":["23143332"],"confidence":"High","gaps":["Which domain of MYD88 mediates ARNO binding was not mapped","Whether the MYD88-ARNO axis operates in cell types beyond endothelium was untested"]},{"year":2017,"claim":"K63-linked ubiquitination in the MYD88 pathway was shown to require combined TRAF6 and Pellino E3 ligase activity, as triple-KO cells (but not single KOs) abolished ubiquitination of IRAK1, IRAK4, and MYD88, redefining the ubiquitin-mediated activation step.","evidence":"TRAF6/Pellino1/Pellino2 triple-KO cells, E3 ligase-inactive knockin mice, in vitro ubiquitination assays","pmids":["28404732"],"confidence":"High","gaps":["Relative contributions of each Pellino isoform in different TLR contexts were unclear","Specific ubiquitination sites on MYD88 were not mapped in this study"]},{"year":2017,"claim":"MYD88 was found to promote myoblast fusion in a cell-autonomous, TLR-independent manner through non-canonical NF-κB and Wnt pathways, expanding its physiological roles beyond immunity to muscle development.","evidence":"Conditional MYD88 knockout, in vitro myoblast differentiation, in vivo muscle overload model, lentiviral overexpression","pmids":["29158520"],"confidence":"High","gaps":["The receptor or upstream signal activating MYD88 during myogenesis was unknown","Whether MYD88 Myddosome assembly occurs in myoblasts was not determined"]},{"year":2020,"claim":"SPOP was identified as the Cullin3-based E3 ligase adaptor that targets MYD88 for proteasomal degradation via its intermediate domain, providing the first defined ubiquitin-proteasome-dependent negative regulatory mechanism for MYD88 protein levels.","evidence":"Co-immunoprecipitation, ubiquitination assays, SPOP KO cells and mice, in vivo Salmonella infection model","pmids":["32365080"],"confidence":"High","gaps":["Whether SPOP-mediated degradation is regulated by stimulation or post-translational modifications was untested","Interplay between SPOP degradation and NEDDylation-mediated negative regulation was uncharacterized"]},{"year":2021,"claim":"Constitutive NF-κB activation by MYD88 L265P was shown to depend on mutation-specific K63-linked ubiquitination by RNF138, which does not modify wild-type MYD88; A20 counteracts this by targeting RNF138 for K48-linked ubiquitination and proteasomal degradation, revealing a mutation-specific regulatory circuit in B-cell lymphomas.","evidence":"Co-immunoprecipitation, ubiquitination assays, RNF138 knockdown, ubiquitination-site mutagenesis, lymphoma growth assays","pmids":["33025009"],"confidence":"High","gaps":["Structural basis for RNF138 selectivity toward L265P over wild-type MYD88 was not resolved","Whether RNF138 targeting could serve as a therapeutic strategy in vivo was untested"]},{"year":2022,"claim":"MYD88 was shown to block autophagic degradation of STING1, promoting STING1-dependent IRF3/JUN-driven ACOD1 expression and itaconate production—a cross-talk mechanism linking TLR and cGAS-STING pathways that protects against endotoxemia and sepsis.","evidence":"Co-immunoprecipitation, MYD88 and STING1 knockout/conditional KO mice, autophagy assays, sepsis model","pmids":["35769880"],"confidence":"High","gaps":["How MYD88 physically blocks STING1 autophagy was mechanistically unresolved","Whether this cross-talk operates in non-myeloid cells was unknown"]},{"year":null,"claim":"Key unresolved questions include the full-length structure of MYD88 bridging the TIR and DD oligomers, the structural mechanism by which L265P spontaneously nucleates the Myddosome, the upstream signals engaging MYD88 in non-immune contexts such as myogenesis and neuronal homeostasis, and the integration of competing post-translational modifications (NEDDylation, SPOP-mediated degradation, K63-ubiquitination) in tuning MYD88 activity in vivo.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length MYD88 structure exists bridging TIR oligomer to DD oligomer","Mechanism of L265P-driven spontaneous Myddosome assembly is structurally unresolved","Integration of NEDDylation, SPOP degradation, and ubiquitination as a regulatory network is uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1,2,3,15,19,21]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,5,6,24]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3,17,21]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[15]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[32]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,2,5,6,8,9,10,13,14,15,20,21,24,31,35]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,11,14,16,19,24,26,29,36]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[6,40]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[24,25,34,42]}],"complexes":["Myddosome (MYD88-IRAK4-IRAK2/IRAK1)"],"partners":["IRAK4","IRAK1","TRAF6","TIRAP","IRF7","IRF5","FADD","ARNO"],"other_free_text":[]},"mechanistic_narrative":"MYD88 is a central adaptor protein in innate immune signaling that couples Toll-like receptors (TLRs) and IL-1 receptor family members to downstream activation of NF-κB, MAPKs, and interferon regulatory factors, thereby orchestrating inflammatory cytokine production, type I interferon induction, and cell fate decisions. Its bipartite architecture—an N-terminal death domain (DD) and a C-terminal TIR domain—enables hierarchical assembly of the Myddosome, a left-handed helical oligomer of 6 MyD88, 4 IRAK4, and 4 IRAK2/IRAK1 death domains that activates IRAK4 kinase activity, IRAK1 phosphorylation, and TRAF6/Pellino-mediated K63-linked ubiquitination to engage NF-κB and IRF5/IRF7 transcription factors [PMID:20485341, PMID:28404732, PMID:15361868, PMID:15665823]. Beyond canonical TLR/IL-1R signaling, MYD88 scaffolds PKCε to TLRs, associates with IFN-γR1 to stabilize cytokine-induced mRNAs, binds ARNO/ARF6 to disrupt vascular integrity independently of NF-κB, blocks autophagic degradation of STING1 to promote ACOD1 expression, and promotes myoblast fusion through non-canonical NF-κB and Wnt signaling [PMID:18458086, PMID:16491077, PMID:23143332, PMID:35769880, PMID:29158520]. The somatic gain-of-function L265P mutation constitutively assembles the Myddosome and drives NF-κB/STAT3 signaling in B-cell lymphomas including diffuse large B-cell lymphoma and Waldenström macroglobulinemia, while autosomal recessive MYD88 deficiency in humans causes susceptibility to life-threatening pyogenic bacterial infections [PMID:21179087, PMID:22931316, PMID:18669862]."},"prefetch_data":{"uniprot":{"accession":"Q99836","full_name":"Myeloid differentiation primary response protein MyD88","aliases":[],"length_aa":296,"mass_kda":33.2,"function":"Adapter protein involved in the Toll-like receptor and IL-1 receptor signaling pathway in the innate immune response (PubMed:15361868, PubMed:18292575, PubMed:33718825, PubMed:37971847). Acts via IRAK1, IRAK2, IRF7 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:15361868, PubMed:19506249, PubMed:24316379, PubMed:40638072). Increases IL-8 transcription (PubMed:9013863). Involved in IL-18-mediated signaling pathway. Activates IRF1 resulting in its rapid migration into the nucleus to mediate an efficient induction of IFN-beta, NOS2/INOS, and IL12A genes. Upon TLR8 activation by GU-rich single-stranded RNA (GU-rich RNA) derived from viruses such as SARS-CoV-2, SARS-CoV and HIV-1, induces IL1B release through NLRP3 inflammasome activation (PubMed:33718825). MyD88-mediated signaling in intestinal epithelial cells is crucial for maintenance of gut homeostasis and controls the expression of the antimicrobial lectin REG3G in the small intestine (By similarity)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q99836/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MYD88","classification":"Not Classified","n_dependent_lines":19,"n_total_lines":1208,"dependency_fraction":0.015728476821192054},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MYD88","total_profiled":1310},"omim":[{"mim_id":"621051","title":"PARALEMMIN 3; PALM3","url":"https://www.omim.org/entry/621051"},{"mim_id":"620165","title":"LEUCINE-RICH REPEATS- AND CALPONIN HOMOLOGY DOMAIN-CONTAINING PROTEIN 4; LRCH4","url":"https://www.omim.org/entry/620165"},{"mim_id":"619990","title":"TRANSMEMBRANE p24 TRAFFICKING PROTEIN 7; TMED7","url":"https://www.omim.org/entry/619990"},{"mim_id":"619181","title":"FAMILY WITH SEQUENCE SIMILARITY 177, MEMBER A1; FAM177A1","url":"https://www.omim.org/entry/619181"},{"mim_id":"619070","title":"LETM1 DOMAIN-CONTAINING PROTEIN 1; LETMD1","url":"https://www.omim.org/entry/619070"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"},{"location":"Mitochondria","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MYD88"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q99836","domains":[{"cath_id":"1.10.533.10","chopping":"23-123","consensus_level":"high","plddt":87.1723,"start":23,"end":123},{"cath_id":"3.40.50.10140","chopping":"162-295","consensus_level":"high","plddt":85.1465,"start":162,"end":295}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99836","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99836-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99836-F1-predicted_aligned_error_v6.png","plddt_mean":80.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MYD88","jax_strain_url":"https://www.jax.org/strain/search?query=MYD88"},"sequence":{"accession":"Q99836","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99836.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99836/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99836"}},"corpus_meta":[{"pmid":"10435584","id":"PMC_10435584","title":"Unresponsiveness of MyD88-deficient mice to endotoxin.","date":"1999","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10435584","citation_count":1570,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21179087","id":"PMC_21179087","title":"Oncogenically active MYD88 mutations in human lymphoma.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21179087","citation_count":1211,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22931316","id":"PMC_22931316","title":"MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.","date":"2012","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22931316","citation_count":968,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9430229","id":"PMC_9430229","title":"MyD88: an adapter that recruits IRAK to the IL-1 receptor complex.","date":"1997","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9430229","citation_count":889,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9575168","id":"PMC_9575168","title":"MyD88, an adapter protein involved in interleukin-1 signaling.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9575168","citation_count":500,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11313410","id":"PMC_11313410","title":"Endotoxin-induced maturation of MyD88-deficient dendritic cells.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11313410","citation_count":371,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12217523","id":"PMC_12217523","title":"A universal role for MyD88 in TLR/IL-1R-mediated signaling.","date":"2002","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/12217523","citation_count":333,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21057262","id":"PMC_21057262","title":"Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency.","date":"2010","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21057262","citation_count":315,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17664289","id":"PMC_17664289","title":"BAFF and MyD88 signals promote a lupuslike disease independent of T cells.","date":"2007","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17664289","citation_count":312,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18178857","id":"PMC_18178857","title":"Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18178857","citation_count":272,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11500829","id":"PMC_11500829","title":"The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol.","date":"2001","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11500829","citation_count":224,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17724133","id":"PMC_17724133","title":"MyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival.","date":"2007","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17724133","citation_count":189,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16491077","id":"PMC_16491077","title":"MyD88-mediated stabilization of interferon-gamma-induced cytokine and chemokine mRNA.","date":"2006","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16491077","citation_count":179,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17548806","id":"PMC_17548806","title":"Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound.","date":"2007","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/17548806","citation_count":153,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11254583","id":"PMC_11254583","title":"Micrococci and peptidoglycan activate TLR2-->MyD88-->IRAK-->TRAF-->NIK-->IKK-->NF-kappaB signal transduction pathway that induces transcription of interleukin-8.","date":"2001","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11254583","citation_count":140,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23143332","id":"PMC_23143332","title":"Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23143332","citation_count":135,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16890209","id":"PMC_16890209","title":"Suppression of MyD88- and TRIF-dependent signaling pathways of Toll-like receptor by (-)-epigallocatechin-3-gallate, a polyphenol component of green tea.","date":"2006","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16890209","citation_count":127,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27869651","id":"PMC_27869651","title":"Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27869651","citation_count":123,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16237099","id":"PMC_16237099","title":"The MyD88-dependent, but not the MyD88-independent, pathway of TLR4 signaling is important in clearing nontypeable haemophilus influenzae from the mouse lung.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16237099","citation_count":123,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32931267","id":"PMC_32931267","title":"Myeloid Differentiation Primary Response Protein 88 (MyD88): The Central Hub of TLR/IL-1R Signaling.","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32931267","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31998072","id":"PMC_31998072","title":"Inflammatory Role of TLR-MyD88 Signaling in Multiple Sclerosis.","date":"2020","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31998072","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20306472","id":"PMC_20306472","title":"SARM inhibits both TRIF- and MyD88-mediated AP-1 activation.","date":"2010","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20306472","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29703722","id":"PMC_29703722","title":"MYD88 L265P Mutation in Lymphoid Malignancies.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29703722","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28404732","id":"PMC_28404732","title":"Roles of the TRAF6 and Pellino E3 ligases in MyD88 and RANKL signaling.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28404732","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33834387","id":"PMC_33834387","title":"MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity.","date":"2021","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/33834387","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19422846","id":"PMC_19422846","title":"Identification and characterization of TLR8 and MyD88 homologs in Atlantic salmon (Salmo salar).","date":"2009","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19422846","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17626835","id":"PMC_17626835","title":"Role of TLR2, TLR4, and MyD88 in murine ozone-induced airway hyperresponsiveness and neutrophilia.","date":"2007","source":"Journal of applied physiology (Bethesda, Md. : 1985)","url":"https://pubmed.ncbi.nlm.nih.gov/17626835","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18308927","id":"PMC_18308927","title":"T cell expression of MyD88 is required for resistance to Toxoplasma gondii.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18308927","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22908325","id":"PMC_22908325","title":"IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis.","date":"2012","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22908325","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18390738","id":"PMC_18390738","title":"Uropathogenic Escherichia coli block MyD88-dependent and activate MyD88-independent signaling pathways in rat testicular cells.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18390738","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17513785","id":"PMC_17513785","title":"The MyD88-independent pathway is not mobilized in human neutrophils stimulated via TLR4.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17513785","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18571728","id":"PMC_18571728","title":"Phosphatase PTP1B negatively regulates MyD88- and TRIF-dependent proinflammatory cytokine and type I interferon production in TLR-triggered macrophages.","date":"2008","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18571728","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35977521","id":"PMC_35977521","title":"The IRAK4 scaffold integrates TLR4-driven TRIF and MYD88 signaling pathways.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35977521","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30401751","id":"PMC_30401751","title":"Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.","date":"2018","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/30401751","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34371036","id":"PMC_34371036","title":"MyD88: At the heart of inflammatory signaling and cardiovascular disease.","date":"2021","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/34371036","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36180407","id":"PMC_36180407","title":"Schisandrin B Attenuates Diabetic Cardiomyopathy by Targeting MyD88 and Inhibiting MyD88-Dependent Inflammation.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/36180407","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14638995","id":"PMC_14638995","title":"Mycobacterial infection in MyD88-deficient mice.","date":"2003","source":"Microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14638995","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12691620","id":"PMC_12691620","title":"Mal and MyD88: adapter proteins involved in signal transduction by Toll-like receptors.","date":"2003","source":"Journal of endotoxin research","url":"https://pubmed.ncbi.nlm.nih.gov/12691620","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15905587","id":"PMC_15905587","title":"Cross talk between MyD88 and focal adhesion kinase pathways.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15905587","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20966070","id":"PMC_20966070","title":"Two human MYD88 variants, S34Y and R98C, interfere with MyD88-IRAK4-myddosome assembly.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20966070","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36333322","id":"PMC_36333322","title":"Osteocytes directly regulate osteolysis via MYD88 signaling in bacterial bone infection.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36333322","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29158520","id":"PMC_29158520","title":"MyD88 promotes myoblast fusion in a cell-autonomous manner.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29158520","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20400509","id":"PMC_20400509","title":"IRAK1 and IRAK4 promote phosphorylation, ubiquitination, and degradation of MyD88 adaptor-like (Mal).","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20400509","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19019456","id":"PMC_19019456","title":"Differential induction of MyD88- and TRIF-dependent pathways in equine monocytes by Toll-like receptor agonists.","date":"2008","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/19019456","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30086464","id":"PMC_30086464","title":"Dual functional roles of the MyD88 signaling in colorectal cancer development.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30086464","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23983209","id":"PMC_23983209","title":"Mal, more than a bridge to MyD88.","date":"2013","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/23983209","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31243359","id":"PMC_31243359","title":"BANK1 interacts with TRAF6 and MyD88 in innate immune signaling in B cells.","date":"2019","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31243359","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23941302","id":"PMC_23941302","title":"Penta-O-galloyl-β-D-glucose ameliorates inflammation by inhibiting MyD88/NF-κB and MyD88/MAPK signalling pathways.","date":"2013","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23941302","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26217083","id":"PMC_26217083","title":"TLR4-HMGB1-, MyD88- and TRIF-dependent signaling in mouse intestinal ischemia/reperfusion injury.","date":"2015","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/26217083","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18458086","id":"PMC_18458086","title":"The scaffold MyD88 acts to couple protein kinase Cepsilon to Toll-like receptors.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18458086","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24444466","id":"PMC_24444466","title":"CD79B and MYD88 mutations in diffuse large B-cell lymphoma.","date":"2013","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24444466","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26261595","id":"PMC_26261595","title":"Significance of TLR4/MyD88 expression in breast cancer.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26261595","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25355920","id":"PMC_25355920","title":"Cytomegalovirus enhances macrophage TLR expression and MyD88-mediated signal transduction to potentiate inducible inflammatory responses.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25355920","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35769880","id":"PMC_35769880","title":"The STING1-MYD88 complex drives ACOD1/IRG1 expression and function in lethal innate immunity.","date":"2022","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/35769880","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30650348","id":"PMC_30650348","title":"Innate Sensing through Mesenchymal TLR4/MyD88 Signals Promotes Spontaneous Intestinal Tumorigenesis.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30650348","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23728346","id":"PMC_23728346","title":"Differential role of MyD88 and Mal/TIRAP in TLR2-mediated gastric tumourigenesis.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23728346","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27979975","id":"PMC_27979975","title":"TLR3 downregulates expression of schizophrenia gene Disc1 via MYD88 to control neuronal morphology.","date":"2016","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/27979975","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19052080","id":"PMC_19052080","title":"MyD88 intrinsically regulates CD4 T-cell responses.","date":"2008","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/19052080","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29358175","id":"PMC_29358175","title":"Extracellular vesicle-mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/29358175","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32365080","id":"PMC_32365080","title":"SPOP promotes ubiquitination and degradation of MyD88 to suppress the innate immune response.","date":"2020","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/32365080","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22544439","id":"PMC_22544439","title":"Bacterial cell wall constituents induce hepcidin expression in macrophages through MyD88 signaling.","date":"2012","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/22544439","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25733102","id":"PMC_25733102","title":"Role of adaptor protein MyD88 in TLR-mediated preconditioning and neuroprotection after acute excitotoxicity.","date":"2015","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/25733102","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33447829","id":"PMC_33447829","title":"An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities.","date":"2021","source":"Blood cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/33447829","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19955209","id":"PMC_19955209","title":"PYK2 interacts with MyD88 and regulates MyD88-mediated NF-kappaB activation in macrophages.","date":"2009","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/19955209","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9344657","id":"PMC_9344657","title":"Genetic structure and chromosomal mapping of MyD88.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9344657","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30203262","id":"PMC_30203262","title":"Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.","date":"2018","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/30203262","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33025009","id":"PMC_33025009","title":"MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33025009","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26388135","id":"PMC_26388135","title":"High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.","date":"2015","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/26388135","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27354411","id":"PMC_27354411","title":"The role of MyD88- and TRIF-dependent signaling in monophosphoryl lipid A-induced expansion and recruitment of innate immunocytes.","date":"2016","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/27354411","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28220253","id":"PMC_28220253","title":"MyD88 in Mycobacterium tuberculosis infection.","date":"2017","source":"Medical microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28220253","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25696843","id":"PMC_25696843","title":"Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis.","date":"2014","source":"Hematology. American Society of Hematology. Education Program","url":"https://pubmed.ncbi.nlm.nih.gov/25696843","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30301877","id":"PMC_30301877","title":"Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma.","date":"2018","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/30301877","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25403892","id":"PMC_25403892","title":"Dendritic cell specific targeting of MyD88 signalling pathways in vivo.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25403892","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24048771","id":"PMC_24048771","title":"MyD88 mediates the decision to die by apoptosis or necroptosis after UV irradiation.","date":"2013","source":"Innate immunity","url":"https://pubmed.ncbi.nlm.nih.gov/24048771","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20702415","id":"PMC_20702415","title":"MTA1 coregulator regulates LPS response via MyD88-dependent signaling.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20702415","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35044826","id":"PMC_35044826","title":"Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35044826","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22075646","id":"PMC_22075646","title":"Opposing roles of RAGE and Myd88 signaling in extensive liver resection.","date":"2011","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/22075646","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21152988","id":"PMC_21152988","title":"Characterization and expression analysis of the myeloid differentiation factor 88 (MyD88) in rock bream Oplegnathus fasciatus.","date":"2010","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21152988","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38353638","id":"PMC_38353638","title":"Gut microbiota regulates host melatonin production through epithelial cell MyD88.","date":"2024","source":"Gut microbes","url":"https://pubmed.ncbi.nlm.nih.gov/38353638","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29502561","id":"PMC_29502561","title":"MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.","date":"2018","source":"Mayo Clinic proceedings","url":"https://pubmed.ncbi.nlm.nih.gov/29502561","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33919485","id":"PMC_33919485","title":"Role of Adaptor Protein Myeloid Differentiation 88 (MyD88) in Post-Subarachnoid Hemorrhage Inflammation: A Systematic Review.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33919485","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36213280","id":"PMC_36213280","title":"Necroptosis of nucleus pulposus cells involved in intervertebral disc degeneration through MyD88 signaling.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36213280","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29061802","id":"PMC_29061802","title":"MYD88 Inhibitor ST2825 Suppresses the Growth of Lymphoma and Leukaemia Cells.","date":"2017","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29061802","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23378931","id":"PMC_23378931","title":"CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma.","date":"2013","source":"ISRN oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23378931","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24285099","id":"PMC_24285099","title":"Dual function of MyD88 in inflammation and oncogenesis: implications for therapeutic intervention.","date":"2014","source":"Current opinion in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24285099","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19949074","id":"PMC_19949074","title":"IL-10 mediates resistance to adoptive transfer experimental autoimmune encephalomyelitis in MyD88(-/-) mice.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19949074","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34289811","id":"PMC_34289811","title":"Evolution of Toll, Spatzle and MyD88 in insects: the problem of the Diptera bias.","date":"2021","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/34289811","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29067999","id":"PMC_29067999","title":"MyD88-dependent dendritic and epithelial cell crosstalk orchestrates immune responses to allergens.","date":"2017","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29067999","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30016685","id":"PMC_30016685","title":"Characterization of MyD88 in Japanese eel, Anguilla japonica.","date":"2018","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30016685","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27864145","id":"PMC_27864145","title":"MyD88 NEDDylation negatively regulates MyD88-dependent NF-κB signaling through antagonizing its ubiquitination.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27864145","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27480067","id":"PMC_27480067","title":"HMGB1 facilitates hypoxia-induced vWF upregulation through TLR2-MYD88-SP1 pathway.","date":"2016","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27480067","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23235763","id":"PMC_23235763","title":"Mutational and expressional analyses of MYD88 gene in common solid cancers.","date":"2012","source":"Tumori","url":"https://pubmed.ncbi.nlm.nih.gov/23235763","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33763070","id":"PMC_33763070","title":"Interplay Between Sialic Acids, Siglec-E, and Neu1 Regulates MyD88- and TRIF-Dependent Pathways for TLR4-Activation During Leishmania donovani Infection.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33763070","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30142469","id":"PMC_30142469","title":"Differential regulation of MyD88- and TRIF-dependent signaling pathways of Toll-like receptors by cardamonin.","date":"2018","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30142469","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22401992","id":"PMC_22401992","title":"MyD88 deficiency results in both cognitive and motor impairments in mice.","date":"2012","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/22401992","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35405183","id":"PMC_35405183","title":"TLR5 recognizes Aeromonas hydrophila flagellin and interacts with MyD88 in Nile tilapia.","date":"2022","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35405183","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27528076","id":"PMC_27528076","title":"Role of MyD88 in adenovirus keratitis.","date":"2016","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27528076","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26546866","id":"PMC_26546866","title":"Polysaccharopeptide exerts immunoregulatory effects via MyD88-dependent signaling pathway.","date":"2015","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/26546866","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35089465","id":"PMC_35089465","title":"Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.","date":"2022","source":"Investigational new drugs","url":"https://pubmed.ncbi.nlm.nih.gov/35089465","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38785969","id":"PMC_38785969","title":"MyD88 and Its Inhibitors in Cancer: Prospects and Challenges.","date":"2024","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/38785969","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16286016","id":"PMC_16286016","title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines.","date":"2005","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/16286016","citation_count":3006,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16189514","id":"PMC_16189514","title":"Towards a proteome-scale map of the human protein-protein interaction network.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16189514","citation_count":2090,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9734363","id":"PMC_9734363","title":"MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways.","date":"1998","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/9734363","citation_count":1231,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9374458","id":"PMC_9374458","title":"IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling.","date":"1997","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9374458","citation_count":944,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11544529","id":"PMC_11544529","title":"Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction.","date":"2001","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11544529","citation_count":940,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20485341","id":"PMC_20485341","title":"Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20485341","citation_count":882,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15665823","id":"PMC_15665823","title":"Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/15665823","citation_count":806,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15361868","id":"PMC_15361868","title":"Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6.","date":"2004","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15361868","citation_count":788,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16751103","id":"PMC_16751103","title":"Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16751103","citation_count":699,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18669862","id":"PMC_18669862","title":"Pyogenic bacterial infections in humans with MyD88 deficiency.","date":"2008","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18669862","citation_count":587,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11960013","id":"PMC_11960013","title":"IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11960013","citation_count":522,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17363736","id":"PMC_17363736","title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17363736","citation_count":522,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7479976","id":"PMC_7479976","title":"Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7479976","citation_count":512,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22541070","id":"PMC_22541070","title":"DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22541070","citation_count":503,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25910212","id":"PMC_25910212","title":"Widespread macromolecular interaction perturbations in human genetic disorders.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25910212","citation_count":454,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10854325","id":"PMC_10854325","title":"Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor.","date":"2000","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10854325","citation_count":436,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26871637","id":"PMC_26871637","title":"Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26871637","citation_count":423,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12865424","id":"PMC_12865424","title":"Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12865424","citation_count":418,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12538665","id":"PMC_12538665","title":"Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4.","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12538665","citation_count":405,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10880445","id":"PMC_10880445","title":"The apoptotic signaling pathway activated by Toll-like receptor-2.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10880445","citation_count":395,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50152,"output_tokens":6710,"usd":0.125553},"stage2":{"model":"claude-opus-4-6","input_tokens":10538,"output_tokens":4590,"usd":0.25116},"total_usd":0.834938,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":62689,"output_tokens":10080,"usd":0.169633},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":14534,"output_tokens":4789,"usd":0.288592}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"MyD88 is recruited to the IL-1 receptor complex following IL-1 stimulation and mediates the association of IRAK with the receptor by binding to both IRAK and the IL-1R heterodimeric signaling complex; ectopic expression of MyD88 or its death domain-containing N-terminus activates NF-κB, while the C-terminus blocks NF-κB activation induced by IL-1 but not TNF.\",\n      \"method\": \"Co-immunoprecipitation, ectopic expression, dominant-negative constructs in cell lines\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP and functional domain dissection, foundational paper with >800 citations\",\n      \"pmids\": [\"9430229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"MyD88 forms homodimers in vivo through DD-DD and Toll-Toll interactions; overexpression activates JNK and NF-κB through its death domain; a point mutation (F56N/MyD88-lpr) preventing DD dimerization blocks these activities; MyD88-induced NF-κB activation is inhibited by dominant-negative TRAF6 and IRAK; MyD88 co-immunoprecipitates with the IL-1R signaling complex in an IL-1-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation, dominant-negative mutants, overexpression in 293 cells, in vivo dimerization assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods, mutagenesis plus functional readouts, >500 citations\",\n      \"pmids\": [\"9575168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"MyD88 is essential for LPS (endotoxin) responses including shock, B cell proliferation, and cytokine secretion by macrophages; MyD88 knockout mice retain LPS-induced NF-κB and MAP kinase activation, revealing a MyD88-independent signaling branch downstream of TLR4.\",\n      \"method\": \"MyD88 knockout mice, LPS challenge, cytokine/NF-κB/MAPK assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple defined phenotypic readouts, >1500 citations, foundational paper\",\n      \"pmids\": [\"10435584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"LPS-induced cytokine production by dendritic cells is MyD88-dependent, but functional DC maturation (upregulation of costimulatory molecules, enhanced APC activity) occurs via a MyD88-independent pathway downstream of TLR4; both pathways require the intracytoplasmic region of TLR4.\",\n      \"method\": \"MyD88 knockout and TLR4 mutant (C3H/HeJ) mice, DC maturation assays, cytokine measurement, in vivo splenic DC analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with multiple orthogonal cellular readouts, >370 citations\",\n      \"pmids\": [\"11313410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Taxol (paclitaxel) LPS-mimetic signaling requires both TLR4 and MyD88 for TNF and NO production; TLR4-dependent but MyD88-independent pathway accounts for MAPK activation and NF-κB nuclear translocation in response to Taxol, mirroring the dual pathway architecture seen with LPS.\",\n      \"method\": \"Primary macrophages from TLR4-null and MyD88-KO mice, dominant-negative MyD88 transfection, luciferase and MAPK assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus dominant-negative approach with multiple readouts\",\n      \"pmids\": [\"11500829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TLR2-mediated IL-8 induction by peptidoglycan signals through a pathway requiring MyD88, IRAK, NIK, IKK, and NF-κB; dominant-negative MyD88 completely blocks NF-κB activation and IL-8 gene expression.\",\n      \"method\": \"Dominant-negative constructs in HEK293 cells expressing TLR2/CD14, NF-κB reporter, RT-PCR\",\n      \"journal\": \"Infection and immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established by dominant-negative approach, single lab\",\n      \"pmids\": [\"11254583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MyD88 acts as a scaffold coupling protein kinase Cε (PKCε) to TLRs; MyD88 is required for LPS-induced PKCε phosphorylation at Ser-346 and Ser-368, 14-3-3β binding, and TLR4 recruitment of PKCε; PKCε phosphorylation at these sites is required for TLR4/TLR2-induced NF-κB activation and IκB degradation.\",\n      \"method\": \"MyD88 KO cells, MyD88 knockdown, MyD88 overexpression, phospho-specific antibodies, reconstitution of PKCε-/- cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal approaches including KO, knockdown, overexpression, and reconstitution\",\n      \"pmids\": [\"18458086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MyD88 stabilizes IFN-γ-induced mRNA transcripts encoding TNF and IP-10 by increasing their half-life; IFN-γ stimulation triggers a physical association between IFN-γR1 and MyD88; transcript stabilization requires activation of MLK3 and p38 MAPK and an AU-rich element in the 3′ UTR.\",\n      \"method\": \"MyD88 KO macrophages, mRNA half-life assays, co-immunoprecipitation (IFN-γR1 and MyD88), kinase inhibitors\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — KO plus Co-IP plus mechanistic mRNA stability assays, multiple orthogonal methods\",\n      \"pmids\": [\"16491077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A peptidomimetic compound (ST2825) modeled on the BB-loop of the MyD88 TIR domain inhibits MyD88 TIR domain homodimerization and recruitment of IRAK1 and IRAK4, causing inhibition of IL-1β-mediated NF-κB activation; it also suppresses CpG/TLR9-induced B cell proliferation and plasma cell differentiation.\",\n      \"method\": \"Co-immunoprecipitation of MyD88 dimerization, peptide inhibitor, in vivo IL-1β cytokine challenge, B cell proliferation assays\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mechanistic inhibitor with direct biochemical readout of dimerization plus cellular and in vivo validation\",\n      \"pmids\": [\"17548806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MyD88-5 (a vertebrate MyD88 family member) is preferentially expressed in neurons, colocalizes in part with mitochondria and JNK3, co-immunoprecipitates with JNK3, and recruits JNK3 from cytosol to mitochondria; MyD88-5-deficient hippocampal neurons are protected from death after oxygen-glucose deprivation.\",\n      \"method\": \"Transgenic MyD88-5/GFP BAC mice, co-immunoprecipitation, subcellular fractionation/copurification with mitochondria, hippocampal neuron KO experiments\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (Co-IP, fractionation, KO with functional readout)\",\n      \"pmids\": [\"17724133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PYK2 (a tyrosine kinase) interacts with MyD88 via MyD88's death domain in vitro and in LPS-stimulated macrophages; PYK2-deficient macrophages exhibit reduced IκB phosphorylation/degradation and decreased NF-κB activation and IL-1β expression, placing PYK2 as a positive regulator of MyD88-dependent NF-κB signaling.\",\n      \"method\": \"Co-immunoprecipitation, PYK2-KO macrophages, IκB phosphorylation/degradation assays, NF-κB reporter\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus KO with functional readout, single lab\",\n      \"pmids\": [\"19955209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Two human MYD88 variants in the death domain, S34Y and R98C, show severely reduced NF-κB activation due to impaired MyD88 homo-oligomerization and reduced IRAK4 interaction, demonstrating that death domain residues Ser-34 and Arg-98 are critical for Myddosome assembly (a death domain post-receptor complex containing MyD88, IRAK4, and IRAK2/1).\",\n      \"method\": \"In vitro cellular NF-κB assays, co-immunoprecipitation, structural modeling of Myddosome\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional mutagenesis combined with structural modeling and Co-IP, single lab\",\n      \"pmids\": [\"20966070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The MYD88 L265P mutation in the TIR domain spontaneously assembles a complex with IRAK1 and IRAK4, leading to IRAK4 kinase activity, IRAK1 phosphorylation, NF-κB signaling, JAK kinase activation of STAT3, and secretion of IL-6, IL-10 and IFN-β, driving ABC DLBCL cell survival; this is a gain-of-function driver mutation not present in wild-type MYD88.\",\n      \"method\": \"RNA interference screening, RNA resequencing, co-immunoprecipitation (IRAK1/IRAK4 complex), lentiviral rescue, kinase activity assays, cytokine measurement\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (RNAi, resequencing, Co-IP, kinase assays, rescue), >1200 citations\",\n      \"pmids\": [\"21179087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"IRAK1 and IRAK4 directly phosphorylate Mal (MyD88 adaptor-like/TIRAP), promoting its ubiquitination and proteasomal degradation; MyD88 itself is not a substrate for either IRAK and does not undergo degradation, revealing a negative feedback mechanism specific to Mal.\",\n      \"method\": \"In vitro kinase assay, co-expression, ubiquitination assay, IRAK1/4 inhibitor, siRNA knockdown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro kinase assay plus cellular validation with inhibitors and siRNA\",\n      \"pmids\": [\"20400509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"IL-1β signals through MYD88 to activate ARF6 via the guanine nucleotide-exchange factor ARNO (CYTH2); ARNO binds directly to MYD88; this MYD88-ARNO-ARF6 pathway disrupts endothelial vascular stability in an NF-κB-independent manner.\",\n      \"method\": \"Human in vitro endothelial cell model, direct binding assay (ARNO-MYD88), ARF6 activation assays, pharmacological inhibition with SecinH3, animal models of arthritis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding demonstrated, multiple orthogonal methods, in vivo validation\",\n      \"pmids\": [\"23143332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In RAS-transformed keratinocytes, MyD88 mediates a cell-intrinsic autocrine loop through IL-1α and IL-1R leading to IκBα phosphorylation and NF-κB activation, required for proinflammatory gene expression and differentiation defects associated with oncogenic RAS transformation.\",\n      \"method\": \"MyD88-/- and IL-1R-/- mice, orthotopic graft experiments, genetic and pharmacological NF-κB inhibition, keratinocyte culture\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus pharmacological approaches with defined molecular pathway and phenotypic readout\",\n      \"pmids\": [\"22908325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MyD88 NEDDylation (conjugation with NEDD8) antagonizes MyD88 ubiquitination; IL-1β stimulation decreases MyD88 NEDDylation while increasing ubiquitination; NEDD8 conjugation negatively regulates MyD88 dimerization and suppresses MyD88-dependent NF-κB signaling; deNEDDylase NEDP1 regulates this process.\",\n      \"method\": \"NEDDylation assay, ubiquitination assay, dimerization assay, NF-κB reporter, IL-1β stimulation, NEDP1 manipulation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical PTM assays with functional NF-κB readout, single lab\",\n      \"pmids\": [\"27864145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Pericyte MyD88 and IRAK4 intrinsically control pericyte migration and conversion to myofibroblasts; pericytes activate TLR2/4-MyD88-dependent NLRP3 inflammasome and IL-1β secretion after injury; specific ablation of MyD88 in pericytes protected against kidney fibrosis and attenuated myofibroblast differentiation.\",\n      \"method\": \"Pericyte-specific MyD88 conditional KO mice, pharmacological IRAK4 inhibition, kidney injury models, cell migration and differentiation assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific conditional KO with defined cellular phenotypes and in vivo validation\",\n      \"pmids\": [\"27869651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TRAF6 E3 ligase activity is not solely responsible for K63-linked ubiquitin chain formation in IL-1/MyD88 signaling; Pellino1 and Pellino2 E3 ligases also generate K63-Ub chains required for TAK1 activation; MyD88 itself is ubiquitylated as part of this process; triple KO of TRAF6/Pellino1/Pellino2 abolishes IL-1-induced K63-Ub chains and ubiquitylation of IRAK1, IRAK4, and MyD88.\",\n      \"method\": \"Triple knockout cells, E3 ligase-inactive TRAF6 knockin mice, in vitro ubiquitination/TAK1 activation assays, IL-1 signaling readouts\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution plus genetic knockin/KO mice with multiple biochemical readouts\",\n      \"pmids\": [\"28404732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MyD88 promotes myoblast fusion in a cell-autonomous manner independent of its role in TLR/IL-1R inflammatory signaling; MyD88 regulates non-canonical NF-κB and canonical Wnt signaling during myogenesis and promotes skeletal muscle growth and overload-induced myofiber hypertrophy.\",\n      \"method\": \"MyD88 conditional deletion and overexpression in myoblasts, in vitro differentiation assays, in vivo muscle regeneration and hypertrophy models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO plus overexpression with defined cellular and in vivo phenotypes\",\n      \"pmids\": [\"29158520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MYD88 L265P protein is present in extracellular vesicles (EVs) shed from Waldenström macroglobulinemia cells; EV-mediated transfer of MYD88 L265P into recipient mast cells and macrophages recruits endogenous wild-type MyD88, triggering myddosome assembly and proinflammatory signaling in the absence of receptor activation.\",\n      \"method\": \"EV isolation/characterization, cellular internalization assays, co-immunoprecipitation of myddosome complex, NF-κB signaling readouts, in vivo mouse bone marrow experiments, patient bone marrow aspirates\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including biochemical, cellular, in vivo, and clinical samples\",\n      \"pmids\": [\"29358175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"E3 ligase RNF138 catalyzes K63-linked nonproteolytic polyubiquitination specifically of MYD88 L265P (not wild-type MYD88), enhancing IRAK recruitment and NF-κB activation; A20 mediates K48-linked polyubiquitination of RNF138 for proteasomal degradation, negatively regulating MYD88 L265P-driven NF-κB signaling.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays (K63 and K48 linkage), knockdown/knockout, site-directed mutagenesis of ubiquitination sites, lymphoma growth assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct biochemical ubiquitination assays with mutagenesis and functional validation\",\n      \"pmids\": [\"33025009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The IRAK4 scaffold (independent of its kinase activity) is required for activation of TRAF6 by both MYD88 and TRIF in the context of TLR4 signaling, integrating these two downstream branches; IRAK4 kinase activity is essential for MYD88 signaling.\",\n      \"method\": \"Genetic loss-of-function, kinase-dead IRAK4 mutants, TLR4-stimulated cell assays, TRAF6 activation readouts\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic approach separating scaffold vs. kinase functions with defined biochemical readouts\",\n      \"pmids\": [\"35977521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Osteocyte MYD88 pathway activation by bacterial PAMPs upregulates RANKL by increasing binding of transcription factors CREB and STAT3 to Rankl enhancers and by suppressing K48-ubiquitination of CREB/CBP and STAT3; mice with MYD88 restoration specifically in osteocytes exhibit osteolysis, while mice lacking osteocyte MYD88 are protected.\",\n      \"method\": \"Cell-type-specific MYD88 KO and restoration mouse models, chromatin binding assays, ubiquitination assays, in vitro bacterial PAMP stimulation, in vivo periodontitis and osteomyelitis models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — cell-type-specific genetic models plus direct biochemical mechanism (chromatin binding, ubiquitination)\",\n      \"pmids\": [\"36333322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MYD88 directly blocks autophagic degradation of STING1, causing subsequent IRF3/JUN-mediated ACOD1 gene transcription and itaconate production; the STING1-MYD88 complex links TLR4 signaling to ACOD1 expression in myeloid cells.\",\n      \"method\": \"Co-immunoprecipitation (MYD88-STING1 complex), conditional myeloid STING1 KO mice, autophagy assays, luciferase reporter for IRF3/JUN, sepsis models\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct binding demonstrated, conditional KO with in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"35769880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SPOP (Cullin3-based ubiquitin ligase adaptor) recognizes the intermediate domain of MyD88 and promotes its ubiquitination and proteasomal degradation, negatively regulating NF-κB signaling and IL-1β production; SPOP-deficient mice show elevated MyD88 and are more susceptible to Salmonella infection.\",\n      \"method\": \"Co-immunoprecipitation (SPOP-MyD88), ubiquitination assay, SPOP knockdown/KO, proteasome inhibition, Salmonella infection model\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct biochemical interaction and ubiquitination assays plus in vivo KO validation\",\n      \"pmids\": [\"32365080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BANK1 interacts with TRAF6 and MyD88 via its TIR domain in co-immunoprecipitation experiments in B cells; the BANK1-40C natural variant shows increased binding to MyD88; BANK1 colocalizes with TLR7 and TLR9 in splenic B cells, and co-localization with MyD88 increases after TLR stimulation.\",\n      \"method\": \"Co-immunoprecipitation, point mutations and decoy peptides, immunofluorescence colocalization in splenic B cells\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP with mutagenesis confirmation, single lab, binding partner identification\",\n      \"pmids\": [\"31243359\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MyD88 functions as a central scaffold/adaptor protein that, upon TLR or IL-1R activation, is recruited to receptor complexes via its TIR domain homodimerization (regulated by NEDDylation, K63-ubiquitination by RNF138/TRAF6/Pellinos, and proteasomal degradation via SPOP), then nucleates the Myddosome death-domain complex with IRAK4 and IRAK1/2, leading to IRAK4 kinase-dependent IRAK1 phosphorylation, TRAF6/Pellino-mediated K63-ubiquitin chain formation, TAK1 activation, and downstream NF-κB and MAPK signaling; gain-of-function mutations such as L265P constitutively trigger myddosome assembly and additional K63-ubiquitination by RNF138, while MyD88 also engages non-canonical partners including ARNO-ARF6 (vascular permeability), PKCε (TLR coupling), STING1 (ACOD1 expression), and JNK3 (neuronal stress), and exerts cell-autonomous roles in myoblast fusion and osteocyte RANKL regulation.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"MyD88 is recruited to the IL-1 receptor complex following IL-1 stimulation and mediates association of IRAK with the receptor; the death domain-containing N-terminus of MyD88 activates NF-κB, and its C-terminus interacts with the IL-1 receptor to block NF-κB activation induced by IL-1 but not TNF.\",\n      \"method\": \"Co-immunoprecipitation, dominant-negative overexpression, deletion mutagenesis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP with domain mutagenesis, foundational paper replicated across multiple studies\",\n      \"pmids\": [\"9430229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"MyD88 acts as a death domain-containing adaptor downstream of the human Toll receptor and IL-1R, coupling these receptors to IRAK and TRAF6 to activate NF-κB; Toll and IL-1R signaling pathways differ in AP-1 activation.\",\n      \"method\": \"Overexpression, dominant-negative constructs, reporter assays in cell lines\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, foundational paper with strong independent replication\",\n      \"pmids\": [\"9734363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"MyD88 is identified as a proximal mediator of IL-1R-induced NF-κB activation alongside IRAK-2; dominant-negative forms of MyD88 attenuate IL-1R-mediated NF-κB activation, and both MyD88 and IRAK-2 associate with the IL-1R signaling complex.\",\n      \"method\": \"Dominant-negative overexpression, co-immunoprecipitation, NF-κB reporter assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus epistasis, replicated by multiple independent labs\",\n      \"pmids\": [\"9374458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"MyD88 has a modular architecture with an N-terminal death domain and C-terminal TIR domain; it forms homodimers via DD-DD and TIR-TIR interactions; overexpression activates NF-κB and JNK through its DD; a point mutation (F56N, MyD88-lpr) preventing DD dimerization blocks NF-κB and JNK activation; MyD88-induced NF-κB activation requires TRAF6 and IRAK.\",\n      \"method\": \"In vivo dimerization assays, co-immunoprecipitation, mutagenesis, reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis plus functional assays, multiple orthogonal methods\",\n      \"pmids\": [\"9575168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"MyD88 gene structure spans five exons with the first exon encoding the complete death domain; the gene is evolutionarily conserved and maps to mouse chromosome 9 distal region and human chromosome 3p22-p21.3; MyD88 is broadly expressed in many adult tissues, not restricted to myeloid cells.\",\n      \"method\": \"Interspecific backcross mapping, Northern blot, RT-PCR, zooblot analysis\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct genetic mapping and expression characterization, single study\",\n      \"pmids\": [\"9344657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"MyD88 knockout mice completely lack LPS shock response, B cell proliferative response, and cytokine secretion by macrophages in response to LPS; however, NF-κB and MAP kinase activation are not abolished, revealing a MyD88-dependent and a MyD88-independent pathway downstream of LPS/TLR4.\",\n      \"method\": \"MyD88 knockout mice, cytokine ELISA, NF-κB activation assays, proliferation assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with multiple defined phenotypic readouts, highly cited foundational study\",\n      \"pmids\": [\"10435584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"MyD88 mediates both apoptosis and NF-κB activation downstream of TLR2 stimulated by bacterial lipoproteins; the two pathways bifurcate at MyD88; MyD88 signals apoptosis via FADD and caspase-8; MyD88 directly binds FADD.\",\n      \"method\": \"Co-immunoprecipitation, dominant-negative constructs, apoptosis assays, caspase activity assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct Co-IP with FADD plus functional epistasis, multiple orthogonal methods\",\n      \"pmids\": [\"10880445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Tollip is present in a pre-formed complex with IRAK before IL-1β stimulation; upon IL-1β treatment, Tollip-IRAK complexes are recruited to the receptor complex through Tollip binding to IL-1RAcP; co-recruited MyD88 triggers IRAK autophosphorylation; IRAK then dissociates from Tollip.\",\n      \"method\": \"Co-immunoprecipitation, overexpression, NF-κB reporter assays\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP revealing ordered assembly, replicated in multiple contexts\",\n      \"pmids\": [\"10854325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"MyD88-deficient dendritic cells can undergo functional maturation (upregulation of costimulatory molecules, enhanced APC activity) in response to LPS despite lacking cytokine production, demonstrating a MyD88-independent pathway downstream of TLR4; TLR9 signaling for DC maturation requires MyD88.\",\n      \"method\": \"MyD88 knockout mice, flow cytometry for costimulatory molecules, in vivo analysis, mixed leukocyte reaction\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with multiple phenotypic readouts, established MyD88-independent pathway\",\n      \"pmids\": [\"11313410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Micrococci and peptidoglycan activate a TLR2→MyD88→IRAK→TRAF6→NIK→IKK→NF-κB pathway leading to IL-8 transcription; dominant-negative MyD88 completely inhibits this pathway.\",\n      \"method\": \"Dominant-negative constructs, NF-κB reporter assays, HEK293 overexpression system\",\n      \"journal\": \"Infection and immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis via dominant negatives defining pathway order, single study\",\n      \"pmids\": [\"11254583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Mal (TIRAP) is an additional TIR-domain adaptor required for TLR4 signaling that forms heterodimers with MyD88; Mal activates NF-κB via IRAK-2 (not IRAK-1, which MyD88 requires); Mal associates directly with TLR4 and a dominant-negative Mal blocks TLR4/LPS-induced NF-κB but not IL-1RI or IL-18R signaling.\",\n      \"method\": \"Co-immunoprecipitation, dominant-negative constructs, reporter assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, reciprocal Co-IP, highly cited foundational paper\",\n      \"pmids\": [\"11544529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IRAK-4 directly interacts with IRAK-1 and TRAF6 in an IL-1-dependent manner; IRAK-4 phosphorylates IRAK-1 and acts upstream of IRAK-1 in MyD88-dependent signaling; dominant-negative IRAK-4 blocks IL-1-induced activation and modification of IRAK-1.\",\n      \"method\": \"Co-immunoprecipitation, kinase assays, dominant-negative constructs, NF-κB reporter assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro kinase assay plus Co-IP and epistasis, replicated widely\",\n      \"pmids\": [\"11960013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MyD88s (alternatively spliced short form lacking the intermediate domain) acts as a dominant-negative inhibitor of IL-1/LPS-induced NF-κB activation because it fails to recruit IRAK-4; in the presence of MyD88s, IRAK-1 is not phosphorylated and does not activate NF-κB.\",\n      \"method\": \"Co-immunoprecipitation, overexpression, NF-κB reporter assays, phosphorylation analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct Co-IP demonstrating differential IRAK-4 recruitment as molecular explanation\",\n      \"pmids\": [\"12538665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"MyD88 forms a complex with IRF7 (but not IRF3) through its death domain interacting with an inhibitory domain of IRF7, leading to activation of IFN-α-dependent promoters; TRAF6 also binds and activates IRF7, and TRAF6 ubiquitin ligase activity is required for IRF7 activation downstream of TLR7/8/9-MyD88 signaling.\",\n      \"method\": \"Co-immunoprecipitation, reporter assays, ubiquitination assays, knockout cells\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct Co-IP defining complex composition with functional validation of each component\",\n      \"pmids\": [\"15361868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IRF-5 acts downstream of the TLR-MyD88 signaling pathway for induction of proinflammatory cytokines (IL-6, IL-12, TNF-α); IRF-5 interacts with and is activated by MyD88 and TRAF6; TLR activation results in nuclear translocation of IRF-5 to activate cytokine gene transcription.\",\n      \"method\": \"Co-immunoprecipitation, IRF-5 knockout mice, subcellular fractionation, reporter assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus direct Co-IP plus nuclear translocation, highly replicated\",\n      \"pmids\": [\"15665823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TIRAP/Mal contains a phosphatidylinositol 4,5-bisphosphate (PIP2) binding domain that mediates its recruitment to the plasma membrane; TIRAP then facilitates delivery of MyD88 to activated TLR4 to initiate signal transduction, establishing a two-step adaptor recruitment mechanism.\",\n      \"method\": \"Subcellular localization by live imaging, PIP2 binding assays, dominant-negative constructs, co-immunoprecipitation\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization with functional consequence established by multiple orthogonal methods\",\n      \"pmids\": [\"16751103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MyD88 increases the half-life (but not synthesis) of IFN-γ-induced mRNA transcripts encoding TNF and IP-10; IFN-γ stimulation triggers physical association between IFN-γR1 and MyD88; transcript stabilization requires MLK3 and p38 MAPK activation and AU-rich elements in the 3′UTR.\",\n      \"method\": \"mRNA half-life assays, co-immunoprecipitation of IFN-γR1 and MyD88, kinase inhibitors, mutagenesis\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct Co-IP plus functional mRNA stability assays with mutagenesis, novel mechanism in single rigorous study\",\n      \"pmids\": [\"16491077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The BB-loop of the MyD88 TIR domain is critical for MyD88 homodimerization and for recruitment of IRAK1 and IRAK4; a peptidomimetic (ST2825) modeled on this BB-loop inhibits MyD88 TIR-domain homodimerization specifically (not DD homodimerization), blocks IRAK1/IRAK4 recruitment, and inhibits IL-1β-mediated NF-κB activation.\",\n      \"method\": \"Co-immunoprecipitation, peptidomimetic inhibition, NF-κB reporter assays, in vivo cytokine assays\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — structure-based inhibitor with mechanistic validation by Co-IP, multiple orthogonal assays\",\n      \"pmids\": [\"17548806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MyD88-5 (a MyD88 family member) is preferentially expressed in neurons, colocalizes in part with mitochondria, co-immunoprecipitates with JNK3, and recruits JNK3 from cytosol to mitochondria; hippocampal neurons from MyD88-5-deficient mice are protected from death after oxygen-glucose deprivation.\",\n      \"method\": \"Transgenic GFP mice, subcellular fractionation, co-immunoprecipitation, knockout neurons, live/death assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct Co-IP plus fractionation with functional KO phenotype, multiple methods\",\n      \"pmids\": [\"17724133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MyD88 acts as a scaffold coupling protein kinase Cε (PKCε) to TLRs; LPS-induced PKCε phosphorylation at Ser-346 and Ser-368 promotes 14-3-3β binding and TLR4 recruitment, all dependent on MyD88 expression; PKCε phosphorylation is required for TLR4- and TLR2-induced NF-κB activation.\",\n      \"method\": \"Co-immunoprecipitation, MyD88 KO mouse cells, MyD88 knockdown, overexpression, phosphorylation-site mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in KO cells plus mutagenesis confirming functional sites\",\n      \"pmids\": [\"18458086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Human individuals with autosomal recessive MyD88 deficiency suffer from recurrent life-threatening pyogenic bacterial infections (especially pneumococcal) but are otherwise healthy, demonstrating that MyD88-dependent TLR/IL-1R signaling is essential for protective immunity to a narrow range of pyogenic bacteria but redundant for defense against most natural infections.\",\n      \"method\": \"Human genetic study, functional cellular assays confirming loss of MyD88-dependent signaling in patient cells\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — natural human loss-of-function with cellular validation, replicated in follow-up cohort studies\",\n      \"pmids\": [\"18669862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Crystal structure of the MyD88-IRAK4-IRAK2 death domain complex reveals a left-handed helical oligomer ('Myddosome') consisting of 6 MyD88, 4 IRAK4, and 4 IRAK2 DDs; assembly is hierarchical (MyD88 recruits IRAK4, then MyD88-IRAK4 recruits IRAK2/IRAK1); composite binding sites are required, and specificities are dictated by molecular complementarity and surface electrostatics.\",\n      \"method\": \"X-ray crystallography, mutagenesis, functional validation of interface residues\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis validation, foundational structural study\",\n      \"pmids\": [\"20485341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Two human MYD88 variants (S34Y and R98C) in the death domain severely reduce NF-κB activation due to impaired MyD88 homo-oligomerization and reduced IRAK4 interaction; MyD88 homo-oligomerization and IRAK4 interaction are also modulated by the MyD88 TIR domain and IRAK4 kinase domain; differential signaling effects suggest receptor specificities exist at the Myddosome level.\",\n      \"method\": \"Functional NF-κB assays, co-immunoprecipitation, structural modeling, epidemiological case-control analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — structure-guided mutagenesis with Co-IP and functional assays, multiple orthogonal methods\",\n      \"pmids\": [\"20966070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"IRAK1 and IRAK4 directly phosphorylate the adaptor Mal, leading to its ubiquitination and proteasomal degradation upon LPS stimulation; MyD88 is NOT a substrate for either IRAK and does not undergo degradation, distinguishing the turnover mechanisms of these two adaptors.\",\n      \"method\": \"In vitro kinase assays, co-immunoprecipitation, ubiquitination assays, siRNA knockdown, IRAK1/4 inhibitor\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay demonstrating direct phosphorylation plus functional validation\",\n      \"pmids\": [\"20400509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The MYD88 L265P mutation in ABC DLBCL constitutively assembles a signaling complex with IRAK1 and IRAK4, leading to IRAK4 kinase activity, IRAK1 phosphorylation, NF-κB signaling, JAK kinase activation of STAT3, and secretion of IL-6, IL-10 and IFN-β; L265P is a gain-of-function driver mutation in the TIR domain at an evolutionarily invariant hydrophobic core residue.\",\n      \"method\": \"RNA interference screening, RNA resequencing, co-immunoprecipitation, kinase activity assays, cytokine measurements, rescue experiments with wild-type vs. mutant MyD88\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including Co-IP of complex, kinase assays, and genetic rescue, replicated widely\",\n      \"pmids\": [\"21179087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MYD88 L265P somatic mutation triggers IRAK-mediated NF-κB signaling; inhibition of MYD88 signaling reduces IκBα and NF-κB p65 phosphorylation and NF-κB nuclear staining in Waldenström macroglobulinemia cells expressing MYD88 L265P.\",\n      \"method\": \"Whole-genome sequencing, Sanger sequencing validation, pharmacological inhibition of MyD88 signaling with functional readouts\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional validation of mutation effect plus pharmacological intervention with mechanistic readouts\",\n      \"pmids\": [\"22931316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MYD88 directly binds ARNO (CYTH2) and signals through ARF6 to disrupt endothelial vascular stability in response to IL-1β via an NF-κB-independent pathway; ARNO binds directly to MyD88, establishing MYD88-ARNO-ARF6 as a proximal IL-1β signaling pathway distinct from the canonical NF-κB route.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, in vitro cell model, animal models of inflammatory arthritis and acute inflammation\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct Co-IP plus multiple in vivo models with defined mechanism, single rigorous study\",\n      \"pmids\": [\"23143332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MyD88 exerts a cell-intrinsic function in RAS-mediated transformation of keratinocytes through an autocrine IL-1α→IL-1R→MyD88→NF-κB loop; loss of MyD88 in keratinocytes expressing oncogenic RAS impairs proinflammatory gene upregulation and differentiation block without abolishing their hyperproliferation.\",\n      \"method\": \"Knockout mice, orthotopic grafts, pharmacological NF-κB inhibition, genetic and pharmacological approaches\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with orthotopic transplants, multiple genetic and pharmacological validation approaches\",\n      \"pmids\": [\"22908325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MyD88 and downstream IRAK4 intrinsically control pericyte migration and conversion to myofibroblasts; MyD88-specific ablation in pericytes protects against kidney fibrosis; pericytes also activate NLRP3 inflammasome through MyD88, leading to IL-1β and IL-18 secretion, which feeds back through pericyte MyD88.\",\n      \"method\": \"Conditional MyD88 knockout in pericytes, IRAK4 inhibitor in vivo, cell migration assays, fibrosis readouts\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional genetic KO with cell-specific phenotype plus pharmacological validation\",\n      \"pmids\": [\"27869651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MyD88 NEDDylation antagonizes its ubiquitination; NEDD8 modification negatively regulates MyD88 dimerization and suppresses MyD88-dependent NF-κB signaling; upon IL-1β stimulation, MyD88 NEDDylation decreases while ubiquitination increases; deNEDDylase NEDP1 regulates this balance.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination/NEDDylation assays, NF-κB reporter assays, NEDP1 overexpression\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical assays with functional readout, single lab study\",\n      \"pmids\": [\"27864145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MyD88 promotes myoblast fusion in a cell-autonomous manner; MyD88 protein levels increase during in vitro myogenesis and muscle growth; deletion of MyD88 impairs myoblast fusion without affecting survival, proliferation, or differentiation; MyD88 regulates non-canonical NF-κB and canonical Wnt signaling during myogenesis.\",\n      \"method\": \"MyD88 conditional knockout, in vitro differentiation assays, in vivo muscle overload model, lentiviral overexpression\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional genetic KO plus OE with specific cell-autonomous phenotype, multiple orthogonal validations\",\n      \"pmids\": [\"29158520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TRAF6 E3 ligase activity is not solely responsible for K63-linked ubiquitin chain formation in IL-1 signaling; Pellino1 and Pellino2 generate the K63-Ub chains required when TRAF6 E3 ligase is inactive; IL-1-induced ubiquitylation of IRAK1, IRAK4, and MyD88 requires combined activity of TRAF6 and Pellinos, as it is abolished only in TRAF6/Pellino1/Pellino2 triple-KO cells.\",\n      \"method\": \"Triple-knockout cells, E3 ligase-inactive knockin mice, in vitro ubiquitination assays, TAK1 activation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro reconstitution plus genetic triple-KO plus knockin mice, multiple orthogonal methods\",\n      \"pmids\": [\"28404732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The constitutively active MyD88 L265P mutant is transferred via extracellular vesicles (EVs) into recipient mast cells and macrophages, where it recruits endogenous wild-type MyD88 and triggers proinflammatory signaling in the absence of receptor activation; MyD88-loaded EVs were detected in bone marrow aspirates of Waldenström macroglobulinemia patients.\",\n      \"method\": \"Extracellular vesicle isolation, fluorescent tracking, co-immunoprecipitation, NF-κB activation assays, in vivo mouse experiments, patient samples\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional EV transfer with mechanistic validation in vitro and in vivo plus patient sample confirmation\",\n      \"pmids\": [\"29358175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SPOP (Cullin 3-based ubiquitin ligase adaptor) recognizes the intermediate domain of MyD88 and degrades it through the proteasome; knockdown or knockout of SPOP leads to elevated MyD88 protein; SPOP negatively regulates NF-κB activity and IL-1β production upon LPS challenge; Spop-deficient mice are more susceptible to Salmonella infection.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, gene knockout (chicken cells and mouse), proteasome inhibition, in vivo infection model\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical identification of E3 adaptor-substrate interaction plus genetic KO in two species with functional readouts\",\n      \"pmids\": [\"32365080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"E3 ligase RNF138 catalyzes K63-linked non-proteolytic polyubiquitination specifically of MYD88 L265P (not wild-type MYD88), enhancing IRAK recruitment and NF-κB activation; A20 mediates K48-linked polyubiquitination of RNF138 for proteasomal degradation, acting as a negative feedback; mutation of MYD88 L265P ubiquitination sites abolishes constitutive NF-κB activation.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, RNF138 knockdown, mutagenesis of ubiquitination sites, NF-κB reporter assays, lymphoma growth assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical dissection with mutagenesis and multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"33025009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IRAK4 scaffold (independent of its kinase activity) is required for activation of TRAF6 by both MYD88 and TRIF downstream of TLR4, integrating the two signaling pathways; IRAK4 kinase activity is essential for MYD88 signaling; IRAK4 thus has dual roles as kinase and scaffold in TLR4 signaling.\",\n      \"method\": \"IRAK4 knockout and kinase-dead knockin cell lines, TRAF6 activation assays, cytokine production assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus kinase-dead knockin with multiple functional readouts, multiple orthogonal methods\",\n      \"pmids\": [\"35977521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MYD88 directly blocks autophagic degradation of STING1, thereby promoting STING1-dependent ACOD1 (IRG1) expression through IRF3/JUN-mediated transcription; MYD88 (not CGAS) favors this STING1-dependent ACOD1 expression; conditional deletion of STING1 in myeloid cells prevents itaconate production and worsens endotoxemia and sepsis.\",\n      \"method\": \"Co-immunoprecipitation, STING1 and MYD88 knockout/conditional knockout mice, autophagy assays, reporter assays, sepsis model\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct Co-IP plus conditional KO in vivo with mechanistic pathway dissection\",\n      \"pmids\": [\"35769880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Osteocyte MYD88 activation by bacterial PAMPs upregulates RANKL by increasing binding of transcription factors CREB and STAT3 to Rankl enhancers and by suppressing K48-ubiquitination of CREB/CBP and STAT3; osteocyte-specific MYD88 restoration in KO mice reconstitutes osteolysis with inflammatory cell infiltration.\",\n      \"method\": \"Conditional MYD88 knockout in osteocytes, conditional MYD88 restoration, ChIP assays, ubiquitination assays, in vivo calvarial injection and periodontitis models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional genetic KO and restoration with ChIP and ubiquitination mechanistic dissection\",\n      \"pmids\": [\"36333322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PYK2 interacts with MyD88 via the death domain of MyD88 in vitro and in macrophages; this interaction increases upon LPS stimulation; PYK2-deficient macrophages show reduced IκB phosphorylation/degradation and decreased NF-κB activation and IL-1β expression, placing PYK2 upstream of NF-κB in MyD88-dependent signaling.\",\n      \"method\": \"Co-immunoprecipitation, PYK2 knockout macrophages, NF-κB reporter assays, phosphorylation assays\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP with KO macrophage functional validation, single lab\",\n      \"pmids\": [\"19955209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BANK1 interacts with TRAF6 and MyD88 via its TIR domain as demonstrated by co-immunoprecipitation; the natural BANK1-40C variant shows increased binding to MyD88; BANK1 colocalizes with TLR7 and TLR9 in B cells, and stimulation increases co-localization with MyD88; BANK1 TIR domain is important for K63-linked polyubiquitination.\",\n      \"method\": \"Co-immunoprecipitation, point mutations, decoy peptides, confocal microscopy, IL-8 production assays\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP with partial functional follow-up, single lab\",\n      \"pmids\": [\"31243359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MyD88 determines cell fate decision (apoptosis vs. necroptosis) after UV irradiation in macrophages; MyD88-deficient macrophages show decreased apoptosis and increased necroptotic signaling (elevated RIP1, TNF-α release, reduced caspase-3 cleavage); TLR4-deficient macrophages phenocopy MyD88-deficient cells, placing TLR4-MyD88 axis as key regulator of UV-induced cell death pathway choice.\",\n      \"method\": \"MyD88 and TLR4 KO macrophages, caspase assays, DNA laddering, TLR-specific KO comparison\",\n      \"journal\": \"Innate immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple KO models with mechanistic cell-death pathway readouts, single lab\",\n      \"pmids\": [\"24048771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TLR3 acts through MYD88 to negatively regulate DISC1 expression in neurons, impairing dendritic arborization; impaired dendritic morphology from TLR3 activation is rescued by MYD88 deficiency or DISC1 overexpression; this MYD88-mediated suppression is cytokine-independent.\",\n      \"method\": \"Cultured neurons, in vivo mouse brain, MYD88 knockout, TLR3 agonists, DISC1 overexpression rescue\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO rescue with specific molecular target identified, single lab\",\n      \"pmids\": [\"27979975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MyD88 L265P is found in normal precursor and mature B lymphocytes from patients with lymphoplasmacytic lymphoma, establishing MYD88 L265P as a preneoplastic (pre-malignant) event; a mouse model based on mutated MYD88 in B cell precursors combined with BCL2 overexpression reconstitutes lymphoplasmacytic lymphoma.\",\n      \"method\": \"Multi-stage B lineage sequencing, whole-genome sequencing, transgenic mouse model\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — sequencing of sorted B cell populations plus in vivo mouse model validation, single study\",\n      \"pmids\": [\"35044826\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MYD88 is a bipartite adaptor protein (N-terminal death domain + C-terminal TIR domain) that, upon TLR/IL-1R activation, is recruited to the receptor complex via TIR-TIR interactions, forms a left-handed helical 'Myddosome' with IRAK4 and IRAK2/IRAK1 death domains (6:4:4 stoichiometry), recruits and activates IRAK4 (which phosphorylates IRAK1), and drives downstream K63-ubiquitination by TRAF6/Pellino E3 ligases to activate NF-κB, MAPK, IRF5, and IRF7; additionally, MYD88 scaffolds PKCε to TLRs, associates with IFN-γR1 to stabilize mRNA post-transcriptionally, directly binds ARNO/ARF6 to disrupt vascular integrity independently of NF-κB, blocks autophagic degradation of STING1 to promote IRF3/JUN-driven ACOD1 expression, regulates cell fate between apoptosis and necroptosis, and promotes myoblast fusion and neuronal homeostasis; gain-of-function mutation L265P spontaneously assembles the Myddosome and drives constitutive NF-κB/STAT3 signaling in B-cell malignancies through mutation-specific RNF138-mediated K63-ubiquitination, while negative regulation is achieved by NEDDylation antagonizing ubiquitination, SPOP-mediated proteasomal degradation via the intermediate domain, and the alternatively spliced MyD88s isoform failing to recruit IRAK4.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MYD88 is a central adaptor protein in innate immune signaling that couples Toll-like receptors (TLRs) and IL-1 receptor family members to downstream NF-κB, MAPK, and JAK-STAT pathways. Upon receptor activation, MYD88 is recruited via its C-terminal TIR domain, homodimerizes, and nucleates the Myddosome—a death-domain oligomeric complex with IRAK4 and IRAK1/2—triggering IRAK4-dependent IRAK1 phosphorylation and TRAF6/Pellino-mediated K63-linked ubiquitin chain formation that activates TAK1 and NF-κB [PMID:9430229, PMID:9575168, PMID:28404732, PMID:35977521]. MYD88 activity is positively regulated by K63-ubiquitination (via RNF138 on the L265P oncogenic mutant) and negatively regulated by NEDDylation and SPOP-mediated proteasomal degradation [PMID:33025009, PMID:27864145, PMID:32365080]. Beyond canonical innate immunity, MYD88 engages non-canonical partners including ARNO/ARF6 to regulate vascular permeability independently of NF-κB, STING1 to control ACOD1/itaconate production, and functions cell-autonomously in myoblast fusion and osteocyte RANKL-driven osteoclastogenesis [PMID:23143332, PMID:35769880, PMID:29158520, PMID:36333322]. The gain-of-function L265P mutation constitutively assembles the Myddosome and drives NF-κB and JAK-STAT3 signaling in activated B-cell diffuse large B-cell lymphoma and Waldenström macroglobulinemia [PMID:21179087, PMID:29358175].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing MYD88 as a signal-bridging adaptor resolved how IL-1R engagement connects to IRAK and NF-κB, identifying the first vertebrate TIR-domain adaptor in cytokine signaling.\",\n      \"evidence\": \"Co-immunoprecipitation and dominant-negative domain constructs in cell lines showing MyD88 bridges IL-1R and IRAK\",\n      \"pmids\": [\"9430229\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural resolution of MyD88–IRAK interface\", \"Stoichiometry of the receptor complex unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrating that MyD88 homodimerizes through both DD–DD and TIR–TIR interactions, and that the F56N mutation blocks dimerization and signaling, established self-oligomerization as the essential activation step upstream of TRAF6 and NF-κB.\",\n      \"evidence\": \"In vivo dimerization assays, point mutagenesis, dominant-negative TRAF6/IRAK epistasis in 293 cells\",\n      \"pmids\": [\"9575168\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Higher-order oligomeric state not resolved\", \"Relative contributions of DD vs TIR dimerization unclear\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"MyD88-knockout mice revealed that while MyD88 is essential for LPS-induced cytokine production and endotoxic shock, a MyD88-independent branch of TLR4 signaling activates NF-κB and MAPKs, defining the bifurcation of TLR4 pathways.\",\n      \"evidence\": \"MyD88-KO mice challenged with LPS; cytokine, NF-κB, and MAPK readouts\",\n      \"pmids\": [\"10435584\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the MyD88-independent adaptor (later TRIF) not yet known\", \"Relative kinetics of the two branches uncharacterized\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Studies across TLR4, TLR2, and Taxol responses solidified the model that MyD88 is the universal adaptor for cytokine production downstream of multiple TLRs, while DC maturation and costimulatory molecule upregulation proceed independently of MyD88.\",\n      \"evidence\": \"MyD88-KO and TLR4-mutant DCs and macrophages with cytokine, costimulatory molecule, and NF-κB/MAPK readouts; dominant-negative MyD88 in TLR2 pathway\",\n      \"pmids\": [\"11313410\", \"11500829\", \"11254583\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of MyD88-independent DC maturation pathway not identified\", \"TLR-specific differences in MyD88 dependency not fully mapped\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Discovery that MyD88 associates with IFN-γR1 and stabilizes inflammatory mRNAs via MLK3/p38 revealed a non-TLR/IL-1R function for MyD88 in post-transcriptional gene regulation.\",\n      \"evidence\": \"MyD88-KO macrophages, mRNA half-life assays, Co-IP of IFN-γR1–MyD88 complex, kinase inhibitors\",\n      \"pmids\": [\"16491077\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct RNA-binding activity of MyD88 not demonstrated\", \"Identity of the RNA-binding effector downstream of p38 unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"A peptidomimetic targeting the MyD88 TIR BB-loop directly blocked homodimerization and IRAK recruitment, providing pharmacological proof that TIR-domain self-association is the druggable initiation step.\",\n      \"evidence\": \"Peptidomimetic ST2825, Co-IP of MyD88 dimerization, NF-κB assays, B cell proliferation\",\n      \"pmids\": [\"17548806\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo pharmacokinetics and selectivity not established\", \"Structural basis of inhibitor–TIR interaction not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identification of the neuronal MyD88 family member MyD88-5/SARM as a JNK3-recruiting adaptor at mitochondria linked the MyD88 scaffold architecture to non-immune neuronal cell death.\",\n      \"evidence\": \"BAC-transgenic mice, Co-IP with JNK3, mitochondrial cofractionation, hippocampal neuron oxygen-glucose deprivation\",\n      \"pmids\": [\"17724133\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relationship between MyD88-5 and canonical MyD88 signaling unclear\", \"Direct mitochondrial targeting mechanism not identified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"The oncogenic MYD88 L265P mutation was shown to spontaneously nucleate a Myddosome with IRAK1/4 and drive NF-κB, JAK-STAT3, and survival signaling in ABC-DLBCL, establishing MYD88 as a gain-of-function oncogene; concurrently, death-domain variants S34Y and R98C defined critical residues for homo-oligomerization and IRAK4 engagement.\",\n      \"evidence\": \"RNAi screen, RNA resequencing, Co-IP of IRAK complex, kinase assays, lentiviral rescue in lymphoma cells; NF-κB assays and structural modeling for DD variants\",\n      \"pmids\": [\"21179087\", \"20966070\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of L265P-driven constitutive dimerization not resolved at atomic level\", \"Contribution of non-NF-κB signaling branches to lymphomagenesis unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Direct binding of ARNO (CYTH2) to MYD88 and consequent ARF6 activation demonstrated a NF-κB-independent branch of MYD88 signaling that controls vascular permeability, expanding MYD88 function beyond transcriptional inflammation.\",\n      \"evidence\": \"Direct binding assay, ARF6 activation assay, pharmacological inhibition (SecinH3), endothelial cell model, arthritis model\",\n      \"pmids\": [\"23143332\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Domain on MYD88 mediating ARNO binding not mapped\", \"Relative contribution in vivo vs. NF-κB arm not quantified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"NEDDylation was identified as a post-translational switch on MYD88 that antagonizes its ubiquitination and dimerization, providing the first evidence that a ubiquitin-like modifier directly tunes MYD88 activation threshold.\",\n      \"evidence\": \"NEDDylation and ubiquitination assays, dimerization assay, NF-κB reporter, IL-1β stimulation\",\n      \"pmids\": [\"27864145\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"NEDDylation sites on MYD88 not mapped\", \"In vivo significance not tested\", \"Independent replication needed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Reconstitution of the K63-ubiquitin chain machinery showed that TRAF6 alone is insufficient; Pellino1/2 E3 ligases cooperate with TRAF6 to ubiquitinate IRAK1, IRAK4, and MYD88 itself, and are required for TAK1 activation, redefining the Myddosome-to-TAK1 signaling node.\",\n      \"evidence\": \"Triple KO cells (TRAF6/Pellino1/2), E3-inactive TRAF6 knockin mice, in vitro ubiquitination and TAK1 activation assays\",\n      \"pmids\": [\"28404732\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific ubiquitination sites on MYD88 not identified\", \"Relative E3 contributions in different cell types unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Cell-autonomous MYD88 function in myoblast fusion and skeletal muscle hypertrophy through non-canonical NF-κB and Wnt signaling established a developmental/regenerative role independent of innate immune signaling.\",\n      \"evidence\": \"Conditional MyD88 deletion and overexpression in myoblasts, in vitro fusion assays, in vivo regeneration and overload hypertrophy\",\n      \"pmids\": [\"29158520\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding partners mediating Wnt cross-talk not identified\", \"Whether TIR or DD domain mediates myogenic function unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extracellular vesicle-borne MYD88 L265P recruits wild-type MyD88 in recipient cells to form a Myddosome without receptor engagement, demonstrating a paracrine mechanism of oncogenic pathway activation.\",\n      \"evidence\": \"EV isolation from WM cells, Co-IP of myddosome in recipient cells, NF-κB readouts, patient bone marrow aspirates\",\n      \"pmids\": [\"29358175\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of WT:L265P needed for activation unknown\", \"Whether EV transfer occurs at biologically meaningful rates in vivo not quantified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"SPOP was identified as a Cullin3-based E3 ligase adaptor that targets MYD88 for proteasomal degradation, establishing a homeostatic negative regulator whose loss amplifies NF-κB and increases susceptibility to Salmonella infection.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, SPOP-KO mice, Salmonella infection model\",\n      \"pmids\": [\"32365080\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitination sites on MYD88 targeted by SPOP not mapped\", \"Whether SPOP regulation is stimulus-dependent not determined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"RNF138 was identified as a K63-ubiquitin ligase selective for the L265P mutant over wild-type MYD88, with A20 counteracting via K48-ubiquitination of RNF138, defining a mutant-specific regulatory axis in lymphoma.\",\n      \"evidence\": \"Ubiquitination assays with linkage-specific antibodies, mutagenesis of ubiquitination sites, lymphoma growth assays\",\n      \"pmids\": [\"33025009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RNF138 selectivity is due to conformational accessibility of L265P not tested structurally\", \"Therapeutic targeting of RNF138 axis not explored\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Separation of IRAK4 scaffold and kinase functions showed that IRAK4 scaffold integrates both MYD88 and TRIF branches at TLR4 to activate TRAF6, while kinase activity is specifically essential for MYD88-dependent signaling.\",\n      \"evidence\": \"Kinase-dead IRAK4 mutants, genetic loss-of-function, TLR4-stimulated cell assays\",\n      \"pmids\": [\"35977521\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for scaffold-only vs. kinase-dependent functions not resolved\", \"Whether scaffold function requires IRAK4 oligomerization unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"MYD88 in osteocytes was shown to upregulate RANKL by stabilizing CREB and STAT3 at Rankl enhancers via suppression of their K48-ubiquitination, providing a direct mechanistic link from innate sensing to osteoclastogenesis-driven bone loss.\",\n      \"evidence\": \"Osteocyte-specific MYD88 KO and restoration mice, chromatin binding assays, ubiquitination assays, periodontitis/osteomyelitis models\",\n      \"pmids\": [\"36333322\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase whose K48 activity on CREB/STAT3 is suppressed by MYD88 not identified\", \"Whether this mechanism operates in non-infectious bone diseases unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"MYD88 directly blocks autophagic degradation of STING1, coupling TLR4 signaling to IRF3/JUN-dependent ACOD1 transcription and itaconate production, revealing a novel MYD88–STING1 crosstalk axis.\",\n      \"evidence\": \"Co-IP of MYD88–STING1, myeloid STING1 conditional KO mice, autophagy flux assays, luciferase reporters, sepsis models\",\n      \"pmids\": [\"35769880\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Domain of MYD88 mediating STING1 binding not mapped\", \"Whether this pathway is active in non-myeloid cells unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include the precise ubiquitination sites on MYD88 that regulate its activity, the structural basis for L265P constitutive oligomerization at atomic resolution, the mechanism by which MYD88 engages non-immune developmental pathways (myogenesis, Wnt), and whether the MYD88–STING1 and MYD88–ARNO axes can be therapeutically dissected from canonical NF-κB signaling.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"MYD88 ubiquitination site map absent\", \"Full Myddosome structure with L265P not available\", \"Non-immune MYD88 interactome uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1, 6, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 1, 8]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4, 5, 6, 8, 17, 18, 22]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 5, 6, 12, 14, 15, 23, 24]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [12, 20, 21]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [16, 18, 25]}\n    ],\n    \"complexes\": [\n      \"Myddosome (MyD88–IRAK4–IRAK1/2)\"\n    ],\n    \"partners\": [\n      \"IRAK4\",\n      \"IRAK1\",\n      \"TRAF6\",\n      \"TIRAP\",\n      \"ARNO/CYTH2\",\n      \"STING1\",\n      \"SPOP\",\n      \"RNF138\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"MYD88 is a central adaptor protein in innate immune signaling that couples Toll-like receptors (TLRs) and IL-1 receptor family members to downstream activation of NF-κB, MAPKs, and interferon regulatory factors, thereby orchestrating inflammatory cytokine production, type I interferon induction, and cell fate decisions. Its bipartite architecture—an N-terminal death domain (DD) and a C-terminal TIR domain—enables hierarchical assembly of the Myddosome, a left-handed helical oligomer of 6 MyD88, 4 IRAK4, and 4 IRAK2/IRAK1 death domains that activates IRAK4 kinase activity, IRAK1 phosphorylation, and TRAF6/Pellino-mediated K63-linked ubiquitination to engage NF-κB and IRF5/IRF7 transcription factors [PMID:20485341, PMID:28404732, PMID:15361868, PMID:15665823]. Beyond canonical TLR/IL-1R signaling, MYD88 scaffolds PKCε to TLRs, associates with IFN-γR1 to stabilize cytokine-induced mRNAs, binds ARNO/ARF6 to disrupt vascular integrity independently of NF-κB, blocks autophagic degradation of STING1 to promote ACOD1 expression, and promotes myoblast fusion through non-canonical NF-κB and Wnt signaling [PMID:18458086, PMID:16491077, PMID:23143332, PMID:35769880, PMID:29158520]. The somatic gain-of-function L265P mutation constitutively assembles the Myddosome and drives NF-κB/STAT3 signaling in B-cell lymphomas including diffuse large B-cell lymphoma and Waldenström macroglobulinemia, while autosomal recessive MYD88 deficiency in humans causes susceptibility to life-threatening pyogenic bacterial infections [PMID:21179087, PMID:22931316, PMID:18669862].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"The fundamental question of how IL-1R and Toll receptor signals reach NF-κB was resolved by identifying MYD88 as a bipartite DD–TIR adaptor that is recruited to the receptor complex via its TIR domain and activates IRAK and TRAF6 via its death domain, establishing the core signaling architecture of TLR/IL-1R pathways.\",\n      \"evidence\": \"Co-immunoprecipitation, dominant-negative overexpression, deletion mutagenesis, reporter assays across multiple labs\",\n      \"pmids\": [\"9430229\", \"9734363\", \"9374458\", \"9575168\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Stoichiometry and structural basis of the MYD88 signaling complex were unknown\",\n        \"Whether MYD88 served all TLRs or only a subset was not established\",\n        \"Mechanism of IRAK activation by MYD88 was not resolved\"\n      ]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"The in vivo requirement for MYD88 in innate immunity was established by knockout mice that lacked LPS shock, macrophage cytokine responses, and B cell proliferation—but retained delayed NF-κB activation—revealing a bifurcation into MYD88-dependent and MYD88-independent TLR4 pathways.\",\n      \"evidence\": \"MYD88 knockout mice with cytokine ELISA, NF-κB assays, and proliferation assays\",\n      \"pmids\": [\"10435584\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Identity of the MYD88-independent adaptor (later TRIF) was unknown\",\n        \"Whether MYD88 was required for all TLRs beyond TLR4 had not been tested\"\n      ]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"MYD88 was shown to bifurcate signaling not only toward NF-κB but also toward apoptosis through direct binding of FADD and caspase-8 downstream of TLR2, establishing MYD88 as a decision node for cell fate.\",\n      \"evidence\": \"Co-immunoprecipitation of MyD88–FADD, dominant-negative constructs, caspase activity assays\",\n      \"pmids\": [\"10880445\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How the choice between apoptotic and NF-κB pathways is regulated at MYD88 was not resolved\",\n        \"Whether necroptotic pathways are also governed by MYD88 was unexplored\"\n      ]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"The adaptor TIRAP/Mal was identified as a TIR-domain heterodimer partner that bridges TLR4 to MYD88, establishing a two-adaptor recruitment model later shown to involve PIP2-mediated membrane targeting of TIRAP.\",\n      \"evidence\": \"Co-immunoprecipitation, dominant-negative Mal, reporter assays; followed by live imaging of PIP2-dependent Mal localization (2006)\",\n      \"pmids\": [\"11544529\", \"16751103\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether TIRAP serves all TLRs or only a subset was debated\",\n        \"Structural basis for the TIRAP–MYD88 heterodimer was not resolved\"\n      ]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"The alternatively spliced isoform MyD88s was shown to act as a natural dominant-negative inhibitor because it lacks the intermediate domain required to recruit IRAK-4, providing the first evidence of negative regulation at the level of MYD88 itself.\",\n      \"evidence\": \"Co-immunoprecipitation demonstrating loss of IRAK-4 binding by MyD88s, phosphorylation analysis, NF-κB reporter assays\",\n      \"pmids\": [\"12538665\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Physiological contexts and regulation of MyD88s splicing were not defined\",\n        \"Whether MyD88s affects IRF signaling was untested\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"MYD88 was connected to interferon regulatory factor signaling: its death domain directly binds IRF7 to drive IFN-α responses downstream of TLR7/8/9, and IRF5 acts downstream of MYD88-TRAF6 to induce proinflammatory cytokine genes, diversifying MYD88 output beyond NF-κB.\",\n      \"evidence\": \"Co-immunoprecipitation, IRF5 knockout mice, nuclear translocation, ubiquitination assays, reporter assays\",\n      \"pmids\": [\"15361868\", \"15665823\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How pathway choice between NF-κB, IRF5, and IRF7 is determined at the Myddosome was unknown\",\n        \"Whether IRF5 and IRF7 are activated through the same or distinct MYD88 complexes was unresolved\"\n      ]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"MYD88 was found to scaffold PKCε to TLRs and to associate with IFN-γR1 for post-transcriptional mRNA stabilization, expanding its function beyond TLR/IL-1R to a non-canonical IFN-γ signaling role and to kinase scaffolding.\",\n      \"evidence\": \"Co-immunoprecipitation in MYD88 KO cells, phosphorylation-site mutagenesis, mRNA half-life assays\",\n      \"pmids\": [\"18458086\", \"16491077\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis for MYD88–IFN-γR1 and MYD88–PKCε interactions was unknown\",\n        \"Whether MYD88 scaffolding of PKCε is relevant to all TLRs was not tested comprehensively\"\n      ]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Human autosomal recessive MYD88 deficiency was shown to cause life-threatening pyogenic bacterial infections but surprising resistance to most other pathogens, defining the essential and redundant roles of MYD88-dependent signaling in human immunity.\",\n      \"evidence\": \"Human genetic study with functional cellular assays confirming loss of MYD88-dependent signaling in patient cells\",\n      \"pmids\": [\"18669862\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Why only a narrow range of pyogenic bacteria requires MYD88-dependent defense was not mechanistically explained\",\n        \"Long-term outcomes and compensatory mechanisms in MYD88-deficient patients were incompletely characterized\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"The crystal structure of the Myddosome (6 MyD88 DD : 4 IRAK4 DD : 4 IRAK2 DD) revealed a left-handed helical assembly with hierarchical recruitment and composite binding interfaces, providing the structural basis for signal amplification and explaining why specific DD mutations (S34Y, R98C) impair oligomerization.\",\n      \"evidence\": \"X-ray crystallography with mutagenesis validation of interface residues; functional assays of human DD variants\",\n      \"pmids\": [\"20485341\", \"20966070\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How the TIR domain oligomer connects to the DD oligomer structurally was not resolved\",\n        \"Full-length MYD88 structure remained unavailable\",\n        \"How Myddosome disassembly is regulated was unknown\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"The MYD88 L265P somatic mutation was identified as an oncogenic driver in ABC-DLBCL that constitutively assembles a Myddosome complex activating IRAK4/IRAK1, NF-κB, and JAK-STAT3 signaling—later confirmed in Waldenström macroglobulinemia—establishing MYD88 as a bona fide oncogene in B-cell malignancies.\",\n      \"evidence\": \"RNAi screening, RNA resequencing, Co-IP of constitutive complex, kinase assays, WGS in WM patients, pharmacological inhibition\",\n      \"pmids\": [\"21179087\", \"22931316\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Mechanism of spontaneous Myddosome assembly by L265P was not structurally resolved\",\n        \"Whether L265P cooperates with specific secondary mutations was unclear\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"MYD88 was shown to signal through a non-canonical NF-κB-independent pathway by directly binding ARNO/CYTH2 to activate ARF6 and disrupt vascular integrity, demonstrating functional outputs beyond transcription factor activation.\",\n      \"evidence\": \"Co-immunoprecipitation, siRNA knockdown, endothelial cell models, in vivo inflammatory arthritis models\",\n      \"pmids\": [\"23143332\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Which domain of MYD88 mediates ARNO binding was not mapped\",\n        \"Whether the MYD88-ARNO axis operates in cell types beyond endothelium was untested\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"K63-linked ubiquitination in the MYD88 pathway was shown to require combined TRAF6 and Pellino E3 ligase activity, as triple-KO cells (but not single KOs) abolished ubiquitination of IRAK1, IRAK4, and MYD88, redefining the ubiquitin-mediated activation step.\",\n      \"evidence\": \"TRAF6/Pellino1/Pellino2 triple-KO cells, E3 ligase-inactive knockin mice, in vitro ubiquitination assays\",\n      \"pmids\": [\"28404732\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Relative contributions of each Pellino isoform in different TLR contexts were unclear\",\n        \"Specific ubiquitination sites on MYD88 were not mapped in this study\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"MYD88 was found to promote myoblast fusion in a cell-autonomous, TLR-independent manner through non-canonical NF-κB and Wnt pathways, expanding its physiological roles beyond immunity to muscle development.\",\n      \"evidence\": \"Conditional MYD88 knockout, in vitro myoblast differentiation, in vivo muscle overload model, lentiviral overexpression\",\n      \"pmids\": [\"29158520\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The receptor or upstream signal activating MYD88 during myogenesis was unknown\",\n        \"Whether MYD88 Myddosome assembly occurs in myoblasts was not determined\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"SPOP was identified as the Cullin3-based E3 ligase adaptor that targets MYD88 for proteasomal degradation via its intermediate domain, providing the first defined ubiquitin-proteasome-dependent negative regulatory mechanism for MYD88 protein levels.\",\n      \"evidence\": \"Co-immunoprecipitation, ubiquitination assays, SPOP KO cells and mice, in vivo Salmonella infection model\",\n      \"pmids\": [\"32365080\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether SPOP-mediated degradation is regulated by stimulation or post-translational modifications was untested\",\n        \"Interplay between SPOP degradation and NEDDylation-mediated negative regulation was uncharacterized\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Constitutive NF-κB activation by MYD88 L265P was shown to depend on mutation-specific K63-linked ubiquitination by RNF138, which does not modify wild-type MYD88; A20 counteracts this by targeting RNF138 for K48-linked ubiquitination and proteasomal degradation, revealing a mutation-specific regulatory circuit in B-cell lymphomas.\",\n      \"evidence\": \"Co-immunoprecipitation, ubiquitination assays, RNF138 knockdown, ubiquitination-site mutagenesis, lymphoma growth assays\",\n      \"pmids\": [\"33025009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis for RNF138 selectivity toward L265P over wild-type MYD88 was not resolved\",\n        \"Whether RNF138 targeting could serve as a therapeutic strategy in vivo was untested\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"MYD88 was shown to block autophagic degradation of STING1, promoting STING1-dependent IRF3/JUN-driven ACOD1 expression and itaconate production—a cross-talk mechanism linking TLR and cGAS-STING pathways that protects against endotoxemia and sepsis.\",\n      \"evidence\": \"Co-immunoprecipitation, MYD88 and STING1 knockout/conditional KO mice, autophagy assays, sepsis model\",\n      \"pmids\": [\"35769880\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How MYD88 physically blocks STING1 autophagy was mechanistically unresolved\",\n        \"Whether this cross-talk operates in non-myeloid cells was unknown\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full-length structure of MYD88 bridging the TIR and DD oligomers, the structural mechanism by which L265P spontaneously nucleates the Myddosome, the upstream signals engaging MYD88 in non-immune contexts such as myogenesis and neuronal homeostasis, and the integration of competing post-translational modifications (NEDDylation, SPOP-mediated degradation, K63-ubiquitination) in tuning MYD88 activity in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No full-length MYD88 structure exists bridging TIR oligomer to DD oligomer\",\n        \"Mechanism of L265P-driven spontaneous Myddosome assembly is structurally unresolved\",\n        \"Integration of NEDDylation, SPOP degradation, and ubiquitination as a regulatory network is uncharacterized\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1, 2, 3, 15, 19, 21]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 5, 6, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 17, 21]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [15]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [32]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 2, 5, 6, 8, 9, 10, 13, 14, 15, 20, 21, 24, 31, 35]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 11, 14, 16, 19, 24, 26, 29, 36]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [6, 40]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [24, 25, 34, 42]}\n    ],\n    \"complexes\": [\n      \"Myddosome (MYD88-IRAK4-IRAK2/IRAK1)\"\n    ],\n    \"partners\": [\n      \"IRAK4\",\n      \"IRAK1\",\n      \"TRAF6\",\n      \"TIRAP\",\n      \"IRF7\",\n      \"IRF5\",\n      \"FADD\",\n      \"ARNO\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}